var title_f16_16_16640="131 I scan in thyroid cancer";
var content_f16_16_16640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Whole body 131-I scan in thyroid cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior view of the head, neck, and chest of a 131-I scan in a patient with differentiated thyroid cancer who underwent thyroidectomy five weeks earlier and had discontinued liothyronine (T3) therapy three weeks earlier. The scan was performed 24 hours after administration of 5 mCi (185 MBq) 131-I. The arrow indicates a thyroid bed remnant with a 24-hour iodine uptake of about 1.5 percent. Physiologic uptake can be seen in the nasopharynx, and physiologic blood pooling of the isotope is seen in the mid-chest. The patient was subsequently treated with 29 mCi (1073 MBq) of 131-I.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16640=[""].join("\n");
var outline_f16_16_16640=null;
var title_f16_16_16641="Pleural effusion radiograph";
var content_f16_16_16641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Right-sided pneumonia with pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dwight A Powell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16641=[""].join("\n");
var outline_f16_16_16641=null;
var title_f16_16_16642="The antiphospholipid syndrome";
var content_f16_16_16642=[" <h1 id=\"patTopicTitle\">",
"  Patient information: The antiphospholipid syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/16/16642/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16642/contributors\" id=\"au5724\">",
"       Peter H Schur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/16/16642/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16642/contributors\" id=\"se5833\">",
"       Robert H Shmerling, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/16/16642/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16642/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?16/16/16642?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ANTIPHOSPHOLIPID SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Phospholipids are present in the membranes that form the surface of cells, including blood cells and endothelial cells that line blood vessels. In some people, the immune system develops antibodies to these phospholipids or to proteins that are attached to them. The presence of these antiphospholipid antibodies may increase the risk of developing blood clots in the veins or arteries and may also cause an increased risk of miscarriage or stillbirth among pregnant women. However, some people have these antibodies and do not develop clots or have miscarriages.",
"    </p>",
"    <p>",
"     People who have these antibodies and develop blood clots or pregnancy-related complications are said to have a syndrome called the antiphospholipid syndrome (APS). Antiphospholipid syndrome is an autoimmune disorder, meaning that it occurs when the body's immune system mistakenly attacks healthy tissues and organs.",
"    </p>",
"    <p>",
"     APS is more common in women and in patients with other autoimmune or rheumatic diseases, particularly systemic lupus erythematosus (SLE). APS is referred to as &ldquo;primary&rdquo; when it occurs alone and as &ldquo;secondary&rdquo; when it occurs in association with another disorder. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ANTIPHOSPHOLIPID SYNDROME SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of APS are related primarily to abnormal blood clotting, miscarriage, or stillbirth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Thrombosis (blood clot)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The presence of antiphospholipid antibodies can increase the risk of developing a thrombosis (blood clot) in a vein or artery. Without treatment, patients often experience repeated clots. Blood flow to and function of important organs can be affected, depending upon where the clot is located.",
"    </p>",
"    <p>",
"     Many organs are susceptible to injury from blood clots. A clot that forms in or blocks an artery can impair blood flow to the brain, causing problems ranging from brief, reversible neurologic symptoms to a stroke that causes permanent brain damage. Impaired blood flow to the kidney can cause problems ranging from mild kidney dysfunction to kidney failure.",
"    </p>",
"    <p>",
"     Clots in large veins can lead to pain and swelling of the affected limb. This is referred to as a deep venous thrombosis or DVT. Legs are most often affected, but the arms can occasionally be involved. In addition to the pain and swelling that such blood clots cause, there is also a risk that a large clot will break free and travel through the heart to the blood vessels of the lungs, where it can block blood flow. A clot that travels is called an embolus; an embolus in the lung is called a pulmonary embolism. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If a large vessel in the lung is blocked due to a pulmonary embolus, a person may feel chest pain, difficulty breathing, and sometimes coughs up of blood. Very large clots can lead to fainting or even death.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Thrombocytopenia",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some patients, APS leads to a decrease in the number of cells known as platelets. This condition is known as thrombocytopenia.",
"    </p>",
"    <p>",
"     Platelets are essential to the normal blood clotting process. When the number of platelets is significantly lowered (to less than 30,000), there is a risk of bleeding, particularly from the nose and gums, into the skin (called petechiae), from the digestive tract, and from the uterus in women. In patients with APS, however, the reduced number of platelets may be associated with an increased risk of blood clots rather than bleeding problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Miscarriages",
"     </span>",
"     &nbsp;&mdash;&nbsp;In women with APS, antiphospholipid antibodies can increase the risk of miscarriage or stillbirth. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Antiphospholipid syndrome and pregnancy'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ANTIPHOSPHOLIPID SYNDROME DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     A diagnosis of APS is based upon a patient's history and laboratory findings. The diagnosis requires the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       An episode of blood clots, one or more miscarriages after the 10",
"       <sup>",
"        th",
"       </sup>",
"       week of pregnancy, three or more miscarriages prior to the 10",
"       <sup>",
"        th",
"       </sup>",
"       week of pregnancy, or one or more premature births prior to the 34",
"       <sup>",
"        th",
"       </sup>",
"       week of pregnancy due to eclampsia.",
"      </li>",
"      <li>",
"       Antiphospholipid antibodies detected with blood testing on at least two different occasions at least 12 weeks apart. Antiphospholipid antibody tests include the lupus anticoagulant, anti-cardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      TREATMENT AND PREVENTION OF BLOOD CLOTS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Anticoagulants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants are medications that prevent an existing blood clot from enlarging and that prevent the formation of additional blood clots. Anticoagulants are commonly, but incorrectly, referred to as blood thinners.",
"    </p>",
"    <p>",
"     Patients with APS are often treated with an injectable anticoagulant called heparin or low molecular weight heparin. In some cases, the heparin is given into a vein while the patient is in the hospital. In other cases, heparin is injected under the skin.",
"    </p>",
"    <p>",
"     There are several types of low molecular weight heparin, including enoxaparin (Lovenox&reg;), dalteparin (Fragmin&reg;), or tinzaparin (Inohep&reg;). These can be injected beneath the skin by the patient, a family member, or a home health nurse. This is usually continued for several days, along with another medication called warfarin (Coumadin&reg;). Warfarin is an anticoagulant medication that is taken by mouth, as a pill. Heparin can be stopped once warfarin levels are stable. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Monitoring of warfarin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Careful monitoring and periodic adjustments in the warfarin dose are typically needed to maintain a level that prevents clots but that does not cause significant bleeding. The blood test used to measure the effects of warfarin is called the prothrombin time (called pro time, or PT). The PT is a laboratory test that measures the time it takes for the clotting mechanism to progress. It is particularly sensitive to the clotting factors affected by warfarin. The PT is used to compute a value known as the INR (or International Normalized Ratio). The INR is a way of expressing the PT in a standardized way; this ensures that results obtained by different laboratories can be reliably compared.",
"    </p>",
"    <p>",
"     The longer it takes the blood to clot, the higher are the PT and INR. The target INR range depends upon the clinical situation. In most cases, the target range is 2 to 3. If the INR is below the target range (ie, under-anticoagulated), there is a risk of clotting. If, on the other hand, the INR is above the target range (ie, over-anticoagulated), there is an increased risk of bleeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Antiplatelet treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Aspirin is another medication sometimes recommended for people with APS. Aspirin inhibits the clumping of platelets; platelets are tiny cell fragments in the blood that have a role in blood clotting. Under normal circumstances, platelets clump together and help form blood clots to stop bleeding when needed.",
"    </p>",
"    <p>",
"     Aspirin is sometimes used in addition to warfarin. It is not usually used as a replacement for warfarin, especially in patients with a history of serious blood clots. Aspirin alone may be recommended for patients who have experienced a single, less severe blood clot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Treatment before and during surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulant and antiplatelet treatments may need to be adjusted before, during, and after surgery or other procedures that have a risk of bleeding. The goal of treatment adjustments is to minimize the risk of new blood clots as well as the risk of excessive bleeding. This usually involves stopping warfarin several days before surgery.",
"    </p>",
"    <p>",
"     The patient may be given heparin before and after surgery, depending upon several factors (the patient's previous history of thrombosis, type of surgery, etc). Warfarin can usually be restarted within 12 hours after surgery. Patients should speak with the provider who prescribes their warfarin to determine the best treatment regimen before and after surgery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TREATMENT OF LOW PLATELETS",
"     </span>",
"    </p>",
"    <p>",
"     Patients with mild thrombocytopenia (low platelet count) due to APS usually require no treatment. In more severe cases, medications (including steroids or immune globulins) are used to help increase the platelet count.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      ANTIPHOSPHOLIPID SYNDROME AND PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Pregnant women with APS have an increased risk of developing a thrombosis (blood clot in a vein or artery) and of having a miscarriage compared with pregnant women without APS. They may also be at risk for other pregnancy-related complications, including preeclampsia and decreased blood flow to the fetus.",
"    </p>",
"    <p>",
"     Several treatments are available to reduce these risks. Treatment depends upon the woman's previous history of blood clots, miscarriage, stillbirth, and preeclampsia and upon her current antibody levels. For women who have antiphospholipid antibodies but no history of blood clots or miscarriage, treatment may or may not be recommended.",
"    </p>",
"    <p>",
"     The following is a general description of available treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Aspirin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low-dose aspirin may be used for pregnant women with APS in combination with other treatments, including heparin injections. Low-dose aspirin can be started before the woman attempts to become pregnant and is usually stopped sometime after two months to 36 weeks of gestation. Aspirin can be restarted after delivery and is usually taken for at least six to eight weeks postpartum.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Heparin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heparin must be given as an injection, either under the skin or into a vein. Most pregnant women who use heparin are taught to give their own injections into the skin.",
"    </p>",
"    <p>",
"     There are two types of heparin: unfractionated and low molecular weight heparin (LMWH).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Unfractionated heparin must be injected twice per day and has a risk of causing excessive bleeding, a low platelet count, and osteoporosis.",
"      </li>",
"      <li>",
"       LMWH is usually injected once per day and has a lower risk of excessive bleeding, low platelet count, and bone thinning (osteoporosis) compared with unfractionated heparin.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Heparin is usually started once pregnancy is confirmed and is usually stopped temporarily for planned procedures (eg, amniocentesis, cesarean section) and when labor begins. Either heparin or warfarin is recommended for six to eight weeks after delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Warfarin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Warfarin is not usually recommended for pregnant women with APS because of the potential risks to the developing fetus. If warfarin is used, it must be stopped before six weeks of pregnancy. It may be restarted after 14 weeks of pregnancy but must be discontinued by 36 weeks of pregnancy. Another anticoagulant (eg, heparin) is usually recommended when warfarin is not used.",
"    </p>",
"    <p>",
"     Warfarin can be restarted after delivery and is often the preferred treatment for women with APS during the postpartum stage (the six to eight weeks following delivery). Warfarin is safe to take while breastfeeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Preventing pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with APS should not use birth control methods that contain estrogen because estrogen can increase the risk of developing a blood clot. A number of other methods of birth control are available, including progestin only pills, an intrauterine device, condoms, a diaphragm, an injection (eg, Depo Provera&reg;), or a surgical procedure. These options are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804453485\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394790\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394805\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=see_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=see_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/antiphosphlipid/antiphospholipid.htm\">",
"        www.ninds.nih.gov/disorders/antiphosphlipid/antiphospholipid.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Family Physicians",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.familydoctor.org/\">",
"        www.familydoctor.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"       <br/>",
"       Phone: 404-633-3777",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?16/16/16642/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?16/16/16642?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16642/abstract/1\">",
"      Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16642/abstract/2\">",
"      Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16642/abstract/3\">",
"      Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100:408.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f16_16_16642=[""].join("\n");
var outline_f16_16_16642=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ANTIPHOSPHOLIPID SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ANTIPHOSPHOLIPID SYNDROME SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ANTIPHOSPHOLIPID SYNDROME DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           TREATMENT AND PREVENTION OF BLOOD CLOTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TREATMENT OF LOW PLATELETS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           ANTIPHOSPHOLIPID SYNDROME AND PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f16_16_16643="Acid reflux (gastroesophageal reflux) in infants";
var content_f16_16_16643=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/16/16643/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16643/contributors\" id=\"au7273\">",
"       Harland S Winter, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/16/16643/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16643/contributors\" id=\"se4415\">",
"       William J Klish, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16643/contributors\" id=\"se4702\">",
"       Steven A Abrams, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/16/16643/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16643/contributors\" id=\"de1276\">",
"       Alison G Hoppin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?16/16/16643?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GASTROESOPHAGEAL REFLUX OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Gastroesophageal reflux (GER) is the medical term for spitting up. It occurs when the stomach contents reflux or back up into the esophagus",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     mouth. Because the stomach naturally produces some acid, reflux is sometimes called acid reflux; other terms include regurgitation and spilling.",
"    </p>",
"    <p>",
"     Reflux is a normal process that occurs in healthy infants, children, and adults. Most infants have brief episodes, during which they spit up milk or formula through the mouth or nose. Uncomplicated reflux does not usually bother the infant, has a low risk of long-term complications, and does not usually require treatment.",
"    </p>",
"    <p>",
"     In contrast, a few infants with gastroesophageal reflux disease (GERD) are irritable, gain weight slowly, develop recurrent pneumonia, or spit up blood. Infants with these signs and symptoms usually require further testing and may require treatment. Although most infants with gastroesophageal reflux disease improve as they grow, some children have symptoms later in childhood.",
"    </p>",
"    <p>",
"     This topic review discusses the symptoms, causes, diagnosis, and treatment of infants with gastroesophageal reflux and gastroesophageal reflux disease. Gastroesophageal reflux disease in older children and adolescents is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/50/32547?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS GASTROESOPHAGEAL REFLUX?",
"     </span>",
"    </p>",
"    <p>",
"     When we eat, food is carried from the mouth to the stomach through the esophagus, a tube-like structure (",
"     <a class=\"graphic graphic_figure graphicRef75218 \" href=\"UTD.htm?13/29/13776\">",
"      figure 1",
"     </a>",
"     ). The esophagus is made of tissue and muscle layers that expand and contract to propel food to the stomach through a series of wave-like movements called peristalsis.",
"    </p>",
"    <p>",
"     At the lower end of the esophagus, where it joins the stomach, there is a circular ring of muscle called the lower esophageal sphincter (LES). When food reaches the LES, it relaxes to allow food to enter the stomach and then contracts to prevent the back-up of food and acid into the esophagus.",
"    </p>",
"    <p>",
"     The ring of muscle does not close completely, allowing the liquids in the stomach to wash back into the esophagus occasionally in all individuals, and particularly in infants. Most of these episodes go unnoticed because the reflux stays in the lower esophagus.",
"    </p>",
"    <p>",
"     As the infant grows and the angle of the stomach and esophagus changes, reflux naturally becomes less frequent. Spitting up disappears in over half of infants by 10 months of age, 80 percent by 18 months, and 98 percent by two years of age [",
"     <a class=\"abstract\" href=\"UTD.htm?16/16/16643/abstract/1\">",
"      1",
"     </a>",
"     ]. Infants who spit up frequently for more than three months are somewhat more likely to have gastrointestinal symptoms later in childhood [",
"     <a class=\"abstract\" href=\"UTD.htm?16/16/16643/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Uncomplicated gastroesophageal reflux",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gastroesophageal reflux is common in infants during the first few months of life, with approximately 50 percent of infants between birth and three months having at least one episode of spitting up per day.",
"    </p>",
"    <p>",
"     Infants who spit up frequently but who feed well, gain weight normally, and are not unusually irritable are usually considered to have \"uncomplicated\" reflux. These infants are sometimes referred to as \"happy spitters\". In this group, spitting up is a natural consequence of the baby's anatomy, because the short esophagus and small stomach allow liquid to escape from the stomach easily. Burping frequently during feeding and limiting activity after feeding may reduce the frequency and amount of spitting up.",
"    </p>",
"    <p>",
"     Specific testing is not usually necessary for children with uncomplicated reflux. If the symptoms become worse, appear for the first time after six months of age, or do not improve by the time the child is 18 to 24 months of age, the child should be reevaluated; a consult with a pediatric gastroenterologist may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Gastroesophageal reflux disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Reflux becomes gastroesophageal reflux disease when acid in the reflux causes irritation or injury to the esophagus. This only occurs in a small percentage of infants who spit up frequently. The amount of reflux required to cause injury varies. In general, damage to the esophagus is more likely to occur when acid refluxes frequently, there is a large amount of reflux, or the esophagus is unable to clear away the acid quickly. The treatments for gastroesophageal reflux disease are designed to prevent one or more of these elements from occurring. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"      \"Gastroesophageal reflux in infants\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some of the signs or symptoms that may indicate GERD include refusing to eat, frequently crying or arching the neck and back as if in pain, choking while spitting up, forceful or projectile vomiting, frequent coughing, or not gaining weight. These behaviors are not normal and further testing is recommended to determine if GERD (or another condition) is the cause. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/18/8486?source=see_link\">",
"      \"Patient information: Poor weight gain in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is often difficult to know if an infant is in pain. In general, an infant who is crying for \"normal\" reasons can be consoled by comforting, distraction, or seeing to the child's needs (hunger, sleep, or a diaper change). Parents who are concerned about their infant's crying should see a healthcare provider to discuss their concerns and possible management strategies. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/7/1140?source=see_link\">",
"      \"Patient information: Colic (excessive crying) in infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Irritability and reflux",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many parents worry that reflux is the cause of their child's irritability or difficulty sleeping. However, clinical studies have shown that reflux does not usually cause pain, and reducing stomach acid does not improve irritability [",
"     <a class=\"abstract\" href=\"UTD.htm?16/16/16643/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Irritability and difficulty sleeping are non-specific problems that can be related to a number of conditions. Infants who are irritable and who regurgitate frequently should be evaluated by a healthcare provider. If there are no other problems, a trial of a milk-free diet and thickened feeds may be recommended. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Reflux treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      REFLUX DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If a child is suspected of having gastroesophageal reflux disease, the first step in the evaluation is a complete medical history and physical examination. The need for further testing depends upon what is found, and may include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Laboratory testing (blood",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       urine tests)",
"      </li>",
"      <li>",
"       An x-ray study to evaluate how well the infant swallows and to evaluate the anatomy of the stomach",
"      </li>",
"      <li>",
"       A procedure, called upper endoscopy, to view the lining of the esophagus",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      REFLUX TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Infants with uncomplicated reflux do not require treatment, although the following changes may be recommended if the infant is bothered by his or her symptoms. Infants with gastroesophageal reflux disease are generally treated first with lifestyle changes, including avoidance of overfeeding and tobacco smoke, a milk-free diet, and thickened feeds.",
"    </p>",
"    <p>",
"     Many infants with symptoms of reflux will improve with conservative measures alone. In one study, over 80 percent of such infants partially or completely improved with conservative measures alone, including thickened feeds, avoidance of tobacco smoke, and trial of a milk-free diet (semi-elemental formula or restriction of milk from mother's diet if breastfed).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Milk-free diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Studies report that 15 to 40 percent of infants with gastroesophageal reflux have a cow's milk protein intolerance, or \"dietary protein-induced gastroenteropathy\" [",
"     <a class=\"abstract\" href=\"UTD.htm?16/16/16643/abstract/4\">",
"      4",
"     </a>",
"     ]. Most children are diagnosed with this condition based upon their symptoms and how they respond to changes in diet; laboratory testing is not usually necessary.",
"    </p>",
"    <p>",
"     The majority of infants with dietary protein gastroenteropathy are sensitive only to cow's milk protein, although some are also sensitive to soy protein. To eliminate these proteins from an infant's diet, breastfeeding mothers need to eliminate all milk and soy products from their own diet. In rare cases, the mother may need to eliminate other proteins, although this should only be done with the advice of a healthcare provider.",
"    </p>",
"    <p>",
"     If the infant's reflux symptoms improve after a two to three week trial, it is reasonable to continue the restricted diet until the child is one year old. At this time, many children are able to tolerate milk without difficulty. If symptoms do not improve, the mother may resume her normal diet.",
"    </p>",
"    <p>",
"     Formula fed infants can be given a hypoallergenic formula that does not contain milk or soy proteins (",
"     <a class=\"graphic graphic_table graphicRef53628 \" href=\"UTD.htm?5/8/5259\">",
"      table 1",
"     </a>",
"     ). This is usually continued for one to two weeks to determine if the infant's reflux improves. If symptoms do not improve, the original formula may be restarted.",
"    </p>",
"    <p>",
"     Almost all infants with a dietary protein intolerance outgrow the problem by one year of age.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Thickened feeds",
"     </span>",
"     &nbsp;&mdash;&nbsp;Thickening formula or expressed breast milk may help to reduce the frequency of acid reflux and is a reasonable approach to reducing symptoms in a healthy baby who is gaining weight normally. For babies under three months of age, or those with allergies, it is best to consult with the child's healthcare provider before thickening feeds or changing formulas. However, thickened feeds are not usually recommended as the sole treatment for infants whose esophagus is injured as a result of acid reflux (esophagitis).",
"    </p>",
"    <p>",
"     In the United States, the usual thickening agent is rice cereal; in other countries, rice starch, carob flour, or locust bean gum may be used. Be sure to check the ingredients in the rice cereal as some brands contain soy protein which may not be well tolerated. To thicken the feed, one ounce (30 mL) of formula or expressed breast milk is usually combined with one tablespoon (15 mL) of rice cereal. The nipple of the bottle may need to be made larger by cross-cutting it, to allow the thickened liquid to pass. Caution should be taken when the hole in the nipple is larger because the child can choke if the formula comes out too fast. For formula-fed infants, premixed \"anti-reflux\" formulas also are available, which contain rice starch to thicken the formula.",
"    </p>",
"    <p>",
"     Women who breastfeed are encouraged to continue doing so; an infant should not be switched to formula for the purpose of thickening the feeds. Breastfeeding may reduce the risk of reflux in infants. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Positioning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infants may have fewer episodes of acid reflux if they can be kept upright and calm for 20 to 30 minutes after a feed (ie, carried on an adult's shoulder, not placed in an infant seat). Parents should avoid over-feeding and allow the infant to stop feeding as soon as he or she seems to lose interest.",
"    </p>",
"    <p>",
"     Like all infants, those with acid reflux should be positioned on the back to sleep. There is no benefit of raising the head of the crib or placing the child to sleep in a car seat. Infants should never be placed on the stomach or side to sleep as this increases the risk of sudden infant death syndrome (SIDS). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/40/7811?source=see_link\">",
"      \"Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Reflux medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;If an infant's symptoms do not improve after a trial of the conservative treatments discussed above, a trial of an acid-suppressing medicine may be recommended. There are a number of medicines available for the treatment of acid reflux in adults. However, the safety and efficacy of these medicines in infants is quite different.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infants with uncomplicated gastroesophageal reflux (\"happy spitters\") do not benefit from medicines that reduce stomach acid or speed emptying of the stomach.",
"      </li>",
"      <li>",
"       Infants with suspected gastroesophageal reflux disease may benefit from a brief trial of a medicine that blocks acid production in the stomach. Omeprazole (Prilosec) and lansoprazole (Prevacid) are best studied in infants. If the symptoms do not improve significantly within a few weeks, the medicine is usually stopped.",
"      </li>",
"      <li>",
"       Antacids (eg, Tums, Maalox) and other medicines (eg, ranitidine [Zantac], famotidine [Pepcid]) are not as effective as omeprazole and lansoprazole in blocking acid, but may help to control symptoms.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     All of these medicine, even antacids, can cause side effects and are not recommended for infants unless you talk to your child's doctor or nurse first.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Infants with acid reflux who also have the following signs or symptoms should be evaluated by a healthcare provider:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bloody stools, severe diarrhea, recurrent vomiting, or vomiting blood",
"      </li>",
"      <li>",
"       Recurrent pneumonia",
"      </li>",
"      <li>",
"       Delayed weight gain",
"      </li>",
"      <li>",
"       The infant has cried for more than two hours",
"      </li>",
"      <li>",
"       Refusing to eat or drink anything for a prolonged period",
"      </li>",
"      <li>",
"       The infant is under three months of age and has forceful vomiting after each feed, but still appears hungry",
"      </li>",
"      <li>",
"       Behavior changes, including lethargy or decreased responsiveness",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H131\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11444597\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/24/43394?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/11/40114?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/53/38738?source=see_link\">",
"      Patient information: Colic (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11444624\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/50/32547?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/18/8486?source=see_link\">",
"      Patient information: Poor weight gain in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/7/1140?source=see_link\">",
"      Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/40/7811?source=see_link\">",
"      Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/gerdinfant/\">",
"        file://digestive.niddk.nih.gov/ddiseases/pubs/gerdinfant/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.naspghan.org/wmspage.cfm?parm1=351\">",
"        www.naspghan.org/wmspage.cfm?parm1=351",
"       </a>",
"       , available in Spanish and Portuguese)",
"      </li>",
"      <li>",
"       Children's Digestive Health and Nutrition Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://gerd.cdhnf.org/\">",
"        file://gerd.cdhnf.org/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       La Leche League",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.llli.org/FAQ/ger.html\">",
"        www.llli.org/FAQ/ger.html",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?16/16/16643/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?16/16/16643?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16643/abstract/1\">",
"      Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16643/abstract/2\">",
"      Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002; 109:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16643/abstract/3\">",
"      Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16643/abstract/4\">",
"      Salvatore S, Vandenplas Y. Gastroesophageal reflux and cow milk allergy: is there a link? Pediatrics 2002; 110:972.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f16_16_16643=[""].join("\n");
var outline_f16_16_16643=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GASTROESOPHAGEAL REFLUX OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS GASTROESOPHAGEAL REFLUX?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           REFLUX DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           REFLUX TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/29/13776\" title=\"figure 1\">",
"           Infant upper GI anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?5/8/5259\" title=\"table 1\">",
"           Infant hypoall formula PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f16_16_16644="Snake bite management algorithm";
var content_f16_16_16644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Algorithm for the management of snake bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 708px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16644=[""].join("\n");
var outline_f16_16_16644=null;
var title_f16_16_16645="Cytomegalovirus immune globulin: Pediatric drug information";
var content_f16_16_16645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cytomegalovirus immune globulin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"    see \"Cytomegalovirus immune globulin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/52/5956?source=see_link\">",
"    see \"Cytomegalovirus immune globulin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CytoGam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CytoGam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immune Globulin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"      see \"Cytomegalovirus immune globulin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of CMV disease in kidney transplant:",
"     </b>",
"     Initial: I.V.: 150 mg/kg within 72 hours of transplant; 100 mg/kg at weeks 2, 4, 6, and 8 after transplant and 50 mg/kg at weeks 12 and 16 after transplant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant (CMV (+) donor and CMV (-) recipient):",
"     </b>",
"     I.V.: 150 mg/kg within 72 hours of transplant, 150 mg/kg at weeks 2, 4, 6, and 8 after transplant; 100 mg/kg at weeks 12 and 16 after transplant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment, CMV disease:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ganciclovir-resistant infection and disease: I.V.: 100 mg/kg/dose weekly in combination with other antivirals (eg, ganciclovir, foscarnet, cidofovir); duration of therapy dependent upon CMV antigenemia assay (pp65) or PCR (Bueno, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pneumonitis, severe: Children and Adolescents: I.V.: 400 mg/kg on days 1, 2, and 7 followed by 200 mg/kg on days 14; if still symptomatic, may administer an additional 200 mg/kg on day 21; use in combination with ganciclovir (Reed, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of CMV disease in kidney transplant:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial dose (within 72 hours of transplant): 150 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-, 4-, 6-, and 8 weeks after transplant: 100 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12 and 16 weeks after transplant: 50 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial dose (within 72 hours of transplant): 150 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-, 4-, 6-, and 8 weeks after transplant: 150 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12 and 16 weeks after transplant: 100 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution. Infuse at minimum rate.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CytoGam&reg;: 50 mg (&plusmn; 10 mg)/mL (50 mL) [contains sodium 20-30 mEq/L, human albumin, and sucrose 50 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. infusion: Does not require further dilution; administer as a 50 mg/mL solution through a dedicated I.V. line containing an in-line 15 micron filter (a 0.2 micron filter is also acceptable) using an infusion pump. Do not mix with other infusions; do not use if turbid. Begin infusion within 6 hours of entering vial, complete infusion within 12 hours of vial entry. Infusion with other products is not recommended; however, if unavoidable, may be piggybacked into an I.V. line of  NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, or dextrose 20% in water. Do not dilute more than 1:2.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Initial infusion: Begin at 15 mg/kg/hour; if there are no infusion-related reactions after 30 minutes, increase to 30 mg/kg/hour; if no infusion-related reactions after 30 minutes, increase to 60 mg/kg/hour for the remainder of the infusion; infusion rate should not exceed 75 mL/hour. Monitor closely after each rate change. If patient develops nausea, back pain, or flushing during infusion, slow the rate or temporarily stop the infusion. Discontinue if blood pressure drops or in case of anaphylactic reaction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Subsequent infusions: Initiate at 15 mg/kg/hour for the first 15 minutes, if no infusion-related reactions, increase to 30 mg/kg/hour for the next 15 minutes; if rate is tolerated, increase to 60 mg/kg/hour and maintain this rate until completion of dose; maximum infusion rate: 60 mg/kg/hour or not to exceed 75 mL/hour.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infusion with other products is not recommended. If unavoidable, may be piggybacked into an I.V. line of sodium chloride, 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, or 20% dextrose in water. Do not dilute more than 1:2. Do not admix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Infusion should begin within 6 hours after entering the vial.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, or heart transplantation [FDA approved in pediatric patients (age not specified) and adults]; concomitant use with ganciclovir should be considered in organ transplants other than kidney from CMV seropositive donors to CMV seronegative recipients; has also been used for CMV treatment in hematopoietic stem cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CytoGam&reg; may be confused with Cytoxan, Gamimune&reg; N",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, acute renal failure, acute respiratory distress syndrome (ARDS), acute tubular necrosis, allergic reactions (systemic), anaphylactic shock, angioneurotic edema, anuria, apnea, aseptic meningitis syndrome (AMS), blood pressure decreased, bronchospasm, bullous dermatitis, BUN increased, cardiac arrest, coma, Coomb&rsquo;s test positive, cyanosis, dyspnea, epidermolysis, erythema multiforme, hemolysis, hypotension, hypoxemia, leukopenia, liver dysfunction, loss of consciousness, oliguria, osmotic nephrosis, pancytopenia, proximal tubular nephropathy, pulmonary edema, renal dysfunction, rigors, seizure, serum creatinine increased, Stevens-Johnson syndrome, thromboembolism, transfusion-related acute lung injury (TRALI), tremor, vascular collapse",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cytomegalovirus immune globulin (CMV-IGIV), other immune globulin preparations, or any component; selective IgA deficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Product is stabilized with albumin. Response to live vaccines may be reduced following immune globulin treatment; refer to package insert or current practice guidelines for recommendations on separation intervals.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity and anaphylactic reactions can occur; monitor vital signs during infusion; discontinue immediately for hypotension or anaphylaxis; immediate treatment (including epinephrine 1:1000) should be available. Systemic allergic reactions are rare; may be treated with epinephrine and diphenhydramine",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Acute renal dysfunction with increased serum creatinine, oliguria, osmotic nephrosis, and/or acute renal failure can rarely occur with administration of immune globulin products; usually within 7 days of use and more likely with products stabilized with sucrose; CytoGam&reg; contains sucrose as a stabilizing agent. Patients at risk for renal failure include the elderly, patients with pre-existing renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications. In patients at risk for renal dysfunction, the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.  Correct any volume depletion prior to therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg); patients with history of migraines may be at a higher risk. Symptoms include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, and nausea and vomiting. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pulmonary events including transfusion-related acute lung injury (TRALI) have been reported; noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function and usually occurs within 1-6 hours after infusion; monitor closely; may be managed with oxygen and respiratory support.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Thrombotic events have been reported with administration of intravenous immune globulin; patients at risk include those with advanced age or a history of atherosclerosis, cardiovascular and/or thrombotic risk factors, or known/suspected hyperviscosity; use with caution in these patients; consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity. Rapid infusion may be a possible risk factor for vascular occlusive events. Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (BUN, serum creatinine prior to initial infusion and periodically thereafter); urine output; vital signs, including blood pressure (throughout infusion); signs/symptoms of infusion-related adverse reactions, anaphylaxis; signs and symptoms of hemolytic anemia; blood viscosity (baseline; in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; weight gain; clinical response",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CMV-IGIV is a preparation of immunoglobulin G (and trace amounts of IgA and IgM) derived from pooled healthy blood donors and contains a high titer of CMV antibodies; administration provides a passive source of antibodies against cytomegalovirus to attenuate or reduce the incidence of serious CMV disease",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life: 8-24 days",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgA content: Trace",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma Source: 2000-5000 donors (5% with top CMV titers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgG subclass (%):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IgG",
"     <sub>",
"      1",
"     </sub>",
"     : 65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IgG",
"     <sub>",
"      2",
"     </sub>",
"     : 28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IgG",
"     <sub>",
"      3",
"     </sub>",
"     : 5.2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IgG",
"     <sub>",
"      4",
"     </sub>",
"     : 1.7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monomers + dimer (%): &ge;95 monomers + dimers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gamma globulin (%): 99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Albumin: 10 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sodium content: 20-30 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sugar content: 5% sucrose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osmolality: &gt;200 mOsm/L",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bowden RA, Fisher LD, Rogers K, et al, &ldquo;Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease After Marrow Transplant,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1991, 164(3):483-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16645/abstract-text/1651360/pubmed\" id=\"1651360\" target=\"_blank\">",
"        1651360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bueno J, Ramil C, and Green M, \"Current Management Strategies for the Prevention and Treatment of Cytomegalovirus Infection in Pediatric Transplant Recipients,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(5):279-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16645/abstract-text/11994033/pubmed\" id=\"11994033\" target=\"_blank\">",
"        11994033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed EC, Bowden RA, Dandliker PS, et al, \"Treatment of Cytomegalovirus Pneumonia With Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients With Bone Marrow Transplants,\" Ann Intern Med, 1988, 109(10):783-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16645/abstract-text/2847610/pubmed\" id=\"2847610\" target=\"_blank\">",
"        2847610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snydman DR, Werner BG, Dougherty NN, et al, &ldquo;Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation. A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 119(10):984-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16645/abstract-text/8214995 /pubmed\" id=\"8214995 \" target=\"_blank\">",
"        8214995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valantine HA, Luikart H, Doyle R, et al, &ldquo;Impact of Cytomegalovirus Hyperimmune Globulin on Outcome After Cardiothoracic Transplantation: A Comparative Study of Combined Prophylaxis With CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2001, 72(10):1647-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16645/abstract-text/11726825/pubmed\" id=\"11726825\" target=\"_blank\">",
"        11726825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12926 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16645=[""].join("\n");
var outline_f16_16_16645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156155\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663230\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046791\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046785\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156128\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046794\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156180\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046788\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046793\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156182\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156179\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046797\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046784\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046783\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299116\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156136\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156138\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046790\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046782\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046796\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046798\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12926|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=related_link\">",
"      Cytomegalovirus immune globulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/52/5956?source=related_link\">",
"      Cytomegalovirus immune globulin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_16_16646="Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus";
var content_f16_16_16646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/16/16646/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16646/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16646/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/16/16646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16646/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/16/16646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16646/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/16/16646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) occurs frequently in women of childbearing age. The relationships between SLE and menstrual function, menopause, and use of hormonal contraceptives are discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy can be associated with the following issues in SLE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In some patients an exacerbation of symptoms can occur",
"     </li>",
"     <li>",
"      Increased fetal loss, in particular in those patients with antiphospholipid syndrome",
"     </li>",
"     <li>",
"      Pre-eclampsia",
"     </li>",
"     <li>",
"      Small for gestational age infants, intrauterine growth retardation, and premature rupture of the membranes",
"     </li>",
"     <li>",
"      Increased risk of maternal mortality",
"     </li>",
"     <li>",
"      Neonatal lupus and congenital complete heart block in offspring of mothers with anti-Ro antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"     \"Pregnancy in women with systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MENSTRUAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual irregularities are common in women with SLE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstrual irregularity, especially oligomenorrhea, is a common clinical feature in women with SLE. As an example, among 94 women with SLE, none older than 45 years or exposed to immunosuppressive or alkylating agents, oligomenorrhea occurred in 54 percent. Menstrual irregularities were associated with higher levels of prolactin, higher disease activity and lower levels of progesterone&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/1\">",
"       1",
"      </a>",
"      ]. These observations suggest that SLE activity may result in hormonal abnormalities that may contribute to menstrual irregularity.",
"     </li>",
"     <li>",
"      Menorrhagia has been noted in 12 to 15 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Thrombocytopenia, antiphospholipid antibodies, and the use of glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonsteroidal antiinflammatory drugs may contribute to the heavy menstrual flow",
"     </li>",
"     <li>",
"      Temporary or even permanent early (or premature) amenorrhea has been noted in 17 to 24 percent of patients. Two major mechanisms have been identified: There is an association of SLE with autoimmune ovarian injury and with the administration of immunosuppressive agents (especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. A retrospective review of women treated for lupus nephritis illustrated the importance of total drug exposure with cyclophosphamide [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/5\">",
"       5",
"      </a>",
"      ]. Sustained early amenorrhea developed in none of 16 treated only with pulse glucocorticoids, 2 of 16 treated with seven monthly pulses of cyclophosphamide, and 9 of 23 treated with 15 or more monthly pulses of cyclophosphamide. Amenorrhea began within the first seven months in one half of affected patients, occurring earlier in women over the age of 25. The amenorrhea was usually permanent, with recovery occurring only in women receiving the shorter pulse cyclophosphamide regimen.",
"      <br/>",
"      <br/>",
"      The age of the patient at which amenorrhea due to therapy with cyclophosphamide occurred was examined in another study of 35 women who underwent pulse cyclophosphamide therapy; the older the woman at the initiation of therapy the more likely she was to experience ovarian failure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/6\">",
"       6",
"      </a>",
"      ]. The administration of as little as 3000 mg of cyclophosphamide was associated with ovarian failure in some older patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H8#H8\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Gonadal toxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these effects, the menstrual cycle also can affect lupus. In particular, lupus may be more likely to flare in the premenstrual period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MENOPAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopause may or may not be associated with a diminution in the symptoms and signs and signs of SLE. The amount of improvement is variable and ranges from none to substantial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. One observational study of over 300 women with SLE noted similar rates of improvement in SLE symptoms in those during the premenopausal, postmenopausal, and perimenopausal periods [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Menopause brings on several new concerns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmenopausal women have a greater risk of coronary disease as do women with SLE, especially those treated with glucocorticoids&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postmenopausal women have a greater risk of osteoporosis as are women with SLE, especially those treated with glucocorticoids&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hormone replacement therapy with estrogen and a progestin can decrease the risk of osteoporosis, and improve the mood and sense of well being and libido. However, these benefits must be weighed against the risks of breast cancer, cardiovascular disease, and stroke that are significantly increased in otherwise healthy postmenopausal women treated with estrogen and a progestin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/15\">",
"     15",
"    </a>",
"    ] as well as those with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estrogen increases the susceptibility to SLE through uncertain mechanisms which may explain the marked female preponderance in this disorder. However, the risk of increased disease activity with estrogen replacement therapy appears to be small [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. The largest study, of 351 postmenopausal women with SLE, suggested only a small increase in the risk of a disease flare in association with estrogen and intermittent progestin use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\", section on 'Hormonal factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been suggested that estrogen replacement therapy may be associated with an increased likelihood of developing SLE. Data from the Nurses' Health Study found that, when compared to women who were never treated with ERT, the relative risk of SLE was 2.5 in current users and 1.8 in past users [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estrogen therapy should be avoided in patients with a history of thromboembolic disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiphospholipid antibodies.",
"   </p>",
"   <p>",
"    Thus, the risks and benefits of hormone replacement therapy must be carefully weighed for each individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HORMONAL CONTRACEPTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar concerns about exacerbation of SLE have been raised with the use of hormonal contraceptives. Older studies suggested an increased risk of exacerbation when patients with SLE received combination oral contraceptives (containing both estrogen and progestin) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/22\">",
"     22",
"    </a>",
"    ]. These studies also suggested that progestin-only contraceptives do not increase risk of activation, but are more often discontinued by patients because of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent, well designed studies, did not find evidence of an association between oral contraceptive use and SLE flares. The following are illustrative observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study 162 Mexican patients with SLE received an oral contraceptive (30 micrograms ethinylestradiol plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      ), levonorgestrel alone, or an IUD [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/26\">",
"       26",
"      </a>",
"      ]. There was no significant difference in the risk of flare among the three groups, although the use of hormone was associated with an increased risk of thrombotic events, and that of IUD with an increased risk of infection.",
"     </li>",
"     <li>",
"      A year-long study randomly assigned 183 North-American women with SLE, but no prior history of thrombosis and without either moderate or high titer antiphospholipid antibodies, to receive either an oral contraceptive (triphasic 35 micrograms",
"      <span class=\"nowrap\">",
"       ethinylestradiol/0.5-1",
"      </span>",
"      mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      ) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/27\">",
"       27",
"      </a>",
"      ]. The incidence rates of severe SLE flares per patient-year (0.084 and 0.087, respectively) were not significantly different for the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, oral contraceptives, containing lower concentrations of estrogen, are probably safe in patients with mild, well-controlled SLE. We avoid their use in women already at increased risk of clotting, especially patients with antiphospholipid antibodies, the nephrotic syndrome,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/23,25,28,29\">",
"     23,25,28,29",
"    </a>",
"    ]. We also avoid use of oral contraceptives in patients with known coronary or cerebrovascular disease, uncontrolled hypertension, migraine headache with focal neurologic symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    women who continue to smoke cigarettes who are &ge;35 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no conclusive data on whether oral contraceptives are safe in SLE patients with severe and active disease. Some data suggest that those patients with active nephritis may be at increased risk of renal exacerbation when exposed to oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Development of SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is whether hormonal contraceptives might promote the development of SLE as may occur with estrogen replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/21\">",
"     21",
"    </a>",
"    ]. A prospective analysis from the Nurses' Health Study found that the relative risk of developing SLE was not significantly different in past users and never users of oral contraceptives when ACR criteria alone were used for the diagnosis of lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/30\">",
"     30",
"    </a>",
"    ]. However, a small and significant increase in risk (1.9-fold) was noted when more stringent criteria were used for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case-controlled study from the United Kingdom showed that current use of a combination estrogen and progestin oral contraceptive was associated with a small but statistically significant increase in relative risk of SLE (RR 1.54 [95% CI 1.15-2.07]) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16646/abstract/31\">",
"     31",
"    </a>",
"    ]. In that study of 788 women with incident SLE and 7817 matched controls, the RR of incident SLE rose from 1.42 to 2.92 as the dose increased from &le;30 micrograms to 50 micrograms of ethinyl estradiol, supporting a dose response effect. Whether this should change prescribing practices for these agents in persons who have a higher than normal risk of SLE (eg, a suggestive family history, incidentally discovered positive ANA, deficiency in early complement components, etc.), is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4692528\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy can be associated with several issues in women with SLE. These include disease exacerbation in some patients; increased risk of fetal loss especially in those with antiphospholipid antibodies; increased risk for pre-eclampsia, small for gestational aged infants, intrauterine growth retardation and premature rupture of the membranes; increased risk of maternal mortality; and increased risk for neonatal lupus and congenital complete heart block in offspring with mothers who have anti-Ro antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Menstrual irregularities, especially oligomenorrhea, are common in women with SLE, and hormonal abnormalities due to increased disease activity may contribute to menstrual irregularity. Thrombocytopenia, antiphospholipid antibodies, and the use of glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonsteroidal antiinflammatory drugs can contribute to menorrhagia. Temporary or even permanent early (or premature) amenorrhea may result from autoimmune ovarian injury or from the administration of cytotoxic agents, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (CYC). Increased age and greater total drug exposure increase the risk of CYC-related ovarian failure. Hormonal affects influence disease; lupus may be more likely to flare in the premenstrual phase of the menstrual cycle. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Menstrual function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Menopause may or may not be associated with a diminution in the symptoms and signs of SLE. The amount of improvement seen ranges from none to substantial. Estrogen-containing hormonal therapy increases the susceptibility to SLE through uncertain mechanisms. However, the risk of increased disease activity with postmenopausal estrogen therapy appears to be small. The risks and benefits of such therapy must be carefully weighed. We avoid estrogen therapy in patients with a history of thromboembolic disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antiphospholipid antibodies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Menopause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral contraceptives, containing relatively low concentrations of estrogen, are probably safe in patients with mild, well-controlled SLE. We avoid the use of such agents in women at increased risk of clotting, including patients with antiphospholipid antibodies, the nephrotic syndrome,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of thrombophlebitis. We also avoid use of oral contraceptives in patients with known coronary or cerebrovascular disease, uncontrolled hypertension, migraine headache with focal neurologic symptoms,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      women who continue to smoke cigarettes who are &ge;35 years of age. Patients with active nephritis may be at increased risk of renal exacerbation when exposed to oral contraceptives. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hormonal contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of oral contraceptives may convey a small increase in risk for the development of SLE. The degree of risk may correlate with increased estrogen dosing. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Development of SLE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/1\">",
"      Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/2\">",
"      HARVEY AM, SHULMAN LE, TUMULTY PA, et al. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 1954; 33:291.",
"     </a>",
"    </li>",
"    <li>",
"     Dubois' Lupus Erythematosus, 3rd, Wallace DJ, Dubois EL (Eds), Lea and Febiger, Philadelphia 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/4\">",
"      LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/5\">",
"      Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/6\">",
"      McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/7\">",
"      Steinberg AD, Steinberg BJ. Lupus disease activity associated with menstrual cycle. J Rheumatol 1985; 12:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/8\">",
"      Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981; 53:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/9\">",
"      S&aacute;nchez-Guerrero J, Villegas A, Mendoza-Fuentes A, et al. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus. Am J Med 2001; 111:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/10\">",
"      Mok CC, Lau CS, Ho CT, Wong RW. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 1999; 28:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/11\">",
"      Fern&aacute;ndez M, Calvo-Al&eacute;n J, Alarc&oacute;n GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum 2005; 52:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/12\">",
"      Urowitz MB, Iba&ntilde;ez D, Jerome D, Gladman DD. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol 2006; 33:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/13\">",
"      Petri M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/14\">",
"      Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/15\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/16\">",
"      S&aacute;nchez-Guerrero J, Gonz&aacute;lez-P&eacute;rez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007; 56:3070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/17\">",
"      Arden NK, Lloyd ME, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994; 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/18\">",
"      Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997; 24:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/19\">",
"      Greenstein B. Hormonal aspects of lupus: therapeutic possibilities. Lupus 1993; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/20\">",
"      Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/21\">",
"      S&aacute;nchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/22\">",
"      Jungers P, Dougados M, P&eacute;lissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/23\">",
"      Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/24\">",
"      Petri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/25\">",
"      Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 1993; 32:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/26\">",
"      S&aacute;nchez-Guerrero J, Uribe AG, Jim&eacute;nez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/27\">",
"      Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/28\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/29\">",
"      Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/30\">",
"      Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16646/abstract/31\">",
"      Bernier MO, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum 2009; 61:476.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4671 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16646=[""].join("\n");
var outline_f16_16_16646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4692528\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MENSTRUAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MENOPAUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HORMONAL CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Development of SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4692528\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_16_16647="Annual incidence RMSF map";
var content_f16_16_16647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Rocky Mountain spotted fever. Number of reported cases, by county - United States, 2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rocky Mountain spotted fever, caused by",
"    <em>",
"     Rickettsia rickettsii",
"    </em>",
"    , is reported throughout much of the United States, reflecting the widespread ranges of the primary tick vectors responsible for transmission (primarily",
"    <em>",
"     Dermacentor variabilis",
"    </em>",
"    in the East and",
"    <em>",
"     Dermacentor andersonii",
"    </em>",
"    in the West, but also",
"    <em>",
"     Rhipicephalus sanguineus",
"    </em>",
"    in some newly recognized focal areas).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Summary of notifiable diseases -- United States, 2007. MMWR Morb Mortal Wkly Rep 2009; 56:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16647=[""].join("\n");
var outline_f16_16_16647=null;
var title_f16_16_16648="Hydroxyurea: Drug information";
var content_f16_16_16648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxyurea: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=see_link\">",
"    see \"Hydroxyurea: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/53/25431?source=see_link\">",
"    see \"Hydroxyurea: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Droxia&reg;;",
"     </li>",
"     <li>",
"      Hydrea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyurea&reg;;",
"     </li>",
"     <li>",
"      Gen-Hydroxyurea;",
"     </li>",
"     <li>",
"      Hydrea&reg;;",
"     </li>",
"     <li>",
"      Mylan-Hydroxyurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Antineoplastic uses:",
"     </b>",
"     Titrate dose to patient response; if WBC count falls to &lt;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or the platelet count to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , therapy should be stopped for at least 3 days and resumed when values rise toward normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic myeloid leukemia (resistant):",
"     </b>",
"     Oral: Continuous therapy: 20-30 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Solid tumors (head and neck cancer, melanoma, ovarian cancer):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Intermittent therapy: 80 mg/kg as a single dose every third day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Continuous therapy: 20-30 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Concomitant therapy with irradiation (head and neck cancer): 80 mg/kg as a single dose every third day starting at least 7 days before initiation of irradiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Sickle cell anemia:",
"     </b>",
"     Oral: Initial: 15 mg/kg/day; if blood counts are in an acceptable range, may increase by 5 mg/kg every 12 weeks until the maximum tolerated dose of 35 mg/kg/day is achieved or the dose that does not produce toxic effects (do not increase dose if blood counts are between acceptable and toxic ranges). Monitor for toxicity every 2 weeks; if toxicity occurs, withhold treatment until the bone marrow recovers, then restart with a dose reduction of 2.5 mg/kg/day; if no toxicity occurs over the next 12 weeks, then the subsequent dose may be increased by 2.5 mg/kg/day every 12 weeks to a maximum tolerated dose (dose which does not produce hematologic toxicity for 24 consecutive weeks). If hematologic toxicity recurs a second time at a specific dose, do not retry that dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Acceptable hematologic ranges:",
"     </i>",
"     Neutrophils &ge;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelets &ge;95,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; hemoglobin &gt;5.3 g/dL, and reticulocytes &ge;95,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     if the hemoglobin concentration is &lt;9 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Toxic hematologic ranges:",
"     </i>",
"     Neutrophils &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelets &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; hemoglobin &lt;4.5 g/dL; and reticulocytes &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     if the hemoglobin concentration is &lt;9 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute myeloid leukemia (AML), cytoreduction (unlabeled use):",
"     </b>",
"     Oral: 50-100 mg/kg/day until WBC &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (Grund, 1977)",
"     <b>",
"      or",
"     </b>",
"     50-60 mg/kg/day until WBC &lt;10,000-20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (Dohner, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Essential thrombocythemia, high-risk (unlabeled use):",
"     </b>",
"     Oral: 500-1000 mg daily; adjust dose to maintain platelets &lt;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (Harrison, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Head and neck cancer (unlabeled dosing; with concurrent radiation therapy and fluorouracil):",
"     </b>",
"     Oral: 1000 mg every 12 hours for 11 doses per cycle (Garden, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypereosinophilic syndrome (unlabeled use):",
"     </b>",
"     Oral: 1000-3000 mg/day (Klion, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Meningioma (unlabeled use):",
"     </b>",
"     Oral: 20 mg/kg once daily (Newton, 2000; Rosenthal, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Polycythemia vera, high-risk (unlabeled use):",
"     </b>",
"     Oral: 15-20 mg/kg/day (Finazzi, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F181043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/53/25431?source=see_link\">",
"      see \"Hydroxyurea: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be based on ideal or actual body weight, whichever is less.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sickle cell anemia (unlabeled use):",
"     </b>",
"     Children &ge;6 months: Oral: Initial: 15-20 mg/kg once daily; may increase by 5 mg/kg/day every 2-6 months to a maximum dose of 30-35 mg/kg/day (Ferster, 2001; Hankins, 2005; Kinney, 1999; Thornburg, 2009; Wang, 2001; Wang, 2011; Zimmerman, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. May require lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F181027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The manufacturer's labeling recommends the following adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sickle cell anemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No adjustment (of initial dose) required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Reduce initial dose to 7.5 mg/kg/day (Yan, 2005); titrate to response/avoidance of toxicity (refer to usual dosing).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD: Reduce initial dose to 7.5 mg/kg/dose (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Other approved indications: Reduction in initial dose is recommended; however, no specific adjustments  are available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     The following adjustments have also been used:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aronoff, 2007: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 20% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer dose after dialysis on dialysis days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 85% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 80% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 75% of dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5528419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; closely monitor for bone marrow toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15598381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cutaneous vasculitic ulcerations: Discontinue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal   toxicity (severe nausea, vomiting, anorexia): Temporarily interrupt treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mucositis (severe): Temporarily interrupt treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Pancreatitis: Discontinue permanently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Antineoplastic uses (CML, head and neck cancer, melanoma, ovarian cancer): WBC &lt;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt treatment (for at least 3 days), may resume when values rise toward normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Sickle cell anemia: Neutrophils &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;4.5 g/dL, or reticulocytes &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with hemoglobin &lt;9 g/dL: Interrupt treatment; following recovery, may resume with a dose reduction of 2.5 mg/kg/day. If no toxicity occurs over the next 12 weeks, subsequent dose may be increased by 2.5 mg/kg/day every 12 weeks to a dose which does not produce hematologic toxicity for 24 consecutive weeks. If hematologic toxicity recurs a second time at a specific dose, do not retry that dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Droxia&reg;: 200 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrea&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer does not recommend opening the capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of melanoma, refractory chronic myelocytic leukemia (CML); recurrent, metastatic, or inoperable ovarian cancer; management (with concomitant radiation therapy) of  squamous cell head and neck cancer (excluding lip cancer); management of sickle cell patients who have had at least three painful crises in the previous 12 months (to reduce frequency of these crises and the need for blood transfusions)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F181057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of essential thrombocythemia, polycythemia vera, hypereosinophilic syndrome; management of hyperleukocytosis due to acute myeloid leukemia (AML); treatment of AML in poor-risk patients; treatment of meningiomas",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydroxyurea may be confused with hydrOXYzine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydrea [U.S., Canada, and multiple international markets] may be confused with Hydra brand name for isoniazid [Japan]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, disorientation, dizziness, drowsiness (dose-related), fever, hallucinations, headache, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cutaneous vasculitic toxicities, dermatomyositis-like skin changes, facial erythema, gangrene, hyperpigmentation, maculopapular rash, nail atrophy, nail discoloration, peripheral erythema, scaling, skin atrophy, skin cancer, skin ulcer, vasculitis ulcerations, violet papules",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, gastrointestinal irritation and mucositis, (potentiated with radiation therapy), nausea, pancreatitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (anemia, leukopenia/neutropenia [common], thrombocytopenia; hematologic recovery: within 2 weeks); macrocytosis, megaloblastic erythropoiesis, secondary leukemias (long-term use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic enzymes increased, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal:  BUN increased, creatinine increased, renal tubular dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Acute diffuse pulmonary infiltrates (rare), dyspnea, pulmonary fibrosis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyurea or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hydrea&reg;: Marked bone marrow suppression (WBC &lt;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or severe anemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Leukopenia and neutropenia commonly occur (thrombocytopenia and anemia are less common); leukopenia/neutropenia occur first. Hematologic toxicity is reversible (rapid) with treatment interruption. Use with caution in patients with a history of prior chemotherapy or radiation therapy; myelosuppression is more common. Correct severe anemia prior to initiating treatment. Hydrea&reg; use is contraindicated in marked bone marrow suppression; should not be used in sickle cell anemia with severe bone marrow suppression (neutrophils &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;4.5 g/dL, or reticulocytes &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     when hemoglobin &lt;9 g/dL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous vasculitic toxicities: Vasculitic ulcerations and gangrene have been reported with hydroxyurea treatment, most often in patients with a history of or receiving concurrent interferon therapy; discontinue hydroxyurea and consider alternate cytoreductive therapy if cutaneous vasculitic toxicity develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Erythrocyte abnormalities: Self-limiting megaloblastic erythropoiesis may be seen early in treatment (may resemble pernicious anemia, but is unrelated to vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     or folic acid deficiency). Plasma iron clearance may be delayed and iron utilization rate (by erythrocytes) may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Hydroxyurea is mutagenic and clastogenic; causes  cellular transformation resulting in tumorigenicity; also considered genotoxic and may be carcinogenic. Treatment of myeloproliferative disorders (eg, polycythemia vera, thrombocythemia) with long-term hydroxyurea is associated with secondary leukemia",
"     </b>",
"     ; it is unknown if this is drug-related or disease-related. Skin cancer has been reported with long-term hydroxyurea use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Hyperuricemia may occur with antineoplastic treatment; adequate hydration and initiation or dosage adjustment of uricosuric agents (eg, allopurinol) may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may require dose reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: Use is not recommended if neutrophils &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;4.5 g/dL, or reticulocytes &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     when hemoglobin &lt;9 g/dL. May cause macrocytosis, which can mask folic acid deficiency; prophylactic fold acid supplementation is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concurrent drug therapy issues:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiretroviral agents: When treated concurrently with hydroxyurea and antiretroviral agents (including didanosine and stavudine), HIV-infected patients are at higher risk for potentially fatal pancreatitis, hepatotoxicity, hepatic failure, and severe peripheral neuropathy; discontinue immediately if signs of these toxicities develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be more sensitive to the effects of hydroxyurea; may require lower doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Patients with a history of radiation therapy are at risk for exacerbation of post irradiation erythema and myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . To decrease risk of exposure, wear gloves when handling and wash hands before and after contact.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and life-threatening adverse events may occur. Should be administered under the supervision of a physician experienced in the treatment of sickle cell anemia",
"     </b>",
"     or in cancer chemotherapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Hydroxyurea may enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: Hydroxyurea may enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and embryotoxicity at doses lower than the usual human dose (based on BSA). Hydroxyurea may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant during treatment and should use effective contraception.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2527156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue hydroxyurea or to discontinue breast-feeding should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3518430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In sickle cell patients, supplemental administration of folic acid is recommended; hydroxyurea may mask development of folic acid deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F181008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Droxia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $54.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $54.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $58.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hydrea Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $145.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hydroxyurea Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $127.73",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F180996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets, renal function and liver function tests, serum uric acid; hemoglobin F levels (sickle cell disease); monitor for cutaneous toxicities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sickle cell disease: Monitor for toxicity every 2 weeks. If toxicity occurs, stop treatment until the bone marrow recovers; restart at 2.5 mg/kg/day less than the dose at which toxicity occurs. If no toxicity occurs over the next 12 weeks, then the subsequent dose should be increased by 2.5 mg/kg/day. Reduced dosage of hydroxyurea alternating with erythropoietin may decrease myelotoxicity and increase levels of fetal hemoglobin in patients who have not been helped by hydroxyurea alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acceptable range:",
"     </i>",
"     Neutrophils &ge;2500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;95,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &gt;5.3 g/dL, and reticulocytes &ge;95,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     if the hemoglobin concentration is &lt;9 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Toxic range:",
"     </i>",
"     Neutrophils &lt;2000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;4.5 g/dL, and reticulocytes &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     if the hemoglobin concentration is &lt;9 g/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F181010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biosupressin (HU);",
"     </li>",
"     <li>",
"      Droxamida (PE);",
"     </li>",
"     <li>",
"      Durea (PE);",
"     </li>",
"     <li>",
"      Hydab (PH);",
"     </li>",
"     <li>",
"      Hydrea (AR, AU, BE, BG, BR, CL, CN, CO, DK, EE, ES, FI, GB, GR, HK, ID, IE, JP, KP, LU, MX, NL, NZ, PK, RU, SE, TH, TW, UY, ZA);",
"     </li>",
"     <li>",
"      Hydrine (SG);",
"     </li>",
"     <li>",
"      Hydrox (PH);",
"     </li>",
"     <li>",
"      Hydroxycarbamid (PL);",
"     </li>",
"     <li>",
"      Hydroxyurea medac (PL, SE);",
"     </li>",
"     <li>",
"      Krabinex (PH);",
"     </li>",
"     <li>",
"      Litalir (AT, CH, CZ, HN, HR, HU);",
"     </li>",
"     <li>",
"      Neodrea (IN);",
"     </li>",
"     <li>",
"      Onco-Carbide (IT);",
"     </li>",
"     <li>",
"      Siklos (FR, GB);",
"     </li>",
"     <li>",
"      Syrea (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antimetabolite which selectively inhibits ribonucleoside diphosphate reductase, preventing the conversion of ribonucleotides to deoxyribonucleotides, halting the cell cycle at the G1/S phase and therefore  has radiation sensitizing activity by maintaining cells in the G",
"     <sub>",
"      1",
"     </sub>",
"     phase and interfering with DNA repair. In sickle cell anemia, hydroxyurea increases red blood cell (RBC) hemoglobin F levels, RBC water content, deformability of sickled cells, and  alters adhesion of RBCs to endothelium.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: Sickle cell anemia: Fetal hemoglobin increase: 4-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily absorbed  (&ge;80%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes widely into tissues (including into the brain); estimated volume of distribution approximates total body water (Gwilt, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 60% via hepatic and GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 75% to 80% bound to serum proteins (Gwilt, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.9-3.9 hours (Gwilt, 1998); Children: Sickle cell anemia: 1.7 hours (range: 0.7-3 hours) (Ware, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (sickle cell anemia: 40% of administered dose)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alvarez O, Miller ST, Wang WC, et al, &ldquo;Effect of Hydroxyurea Treatment on Renal Function Parameters: Results From the Multi-Center Placebo-Controlled BABY HUG Clinical Trial for Infants With Sickle Cell Anemia,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2012, 59(4):668-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/22294512/pubmed\" id=\"22294512\" target=\"_blank\">",
"        22294512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brawley OW, Cornelius LJ, Edwards LR, et al, &ldquo;National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2008, 148(12):932-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/18458271/pubmed\" id=\"18458271\" target=\"_blank\">",
"        18458271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burnett AK, Milligan D, Prentice AG, et al, &ldquo;A Comparison of Low-Dose Cytarabine and Hydroxyurea With or Without All-Trans Retinoic Acid for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 109(6):1114-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/17315155/pubmed\" id=\"17315155\" target=\"_blank\">",
"        17315155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      D&ouml;hner H, Estey EH, Amadori S, et al, &ldquo;Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(3):453-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/19880497/pubmed\" id=\"19880497\" target=\"_blank\">",
"        19880497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferster A, Tahriri P, Vermylen C, et al, &ldquo;Five Years of Experience With Hydroxyurea in Children and Young Adults With Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 97(11):3628-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/11369660/pubmed\" id=\"11369660\" target=\"_blank\">",
"        11369660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finazzi G and Barbui T, &ldquo;How I Treat Patients With Polycythemia Vera,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(12):5104-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/17264301/pubmed\" id=\"17264301\" target=\"_blank\">",
"        17264301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garden AS, Harris J, Vokes EE, et al, &ldquo;Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(14):2856-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/15254053/pubmed\" id=\"15254053\" target=\"_blank\">",
"        15254053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grund FM, Armitage JO, and Burns P, &ldquo;Hydroxyurea in the Prevention of the Effects of Leukostasis in Acute Leukemia,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1977, 137(9):1246-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/268956/pubmed\" id=\"268956\" target=\"_blank\">",
"        268956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gwilt PR and Tracewell WG, &ldquo;Pharmacokinetics and Pharmacodynamics of Hydroxyurea,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1998, 34(5):347-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/9592619/pubmed\" id=\"9592619\" target=\"_blank\">",
"        9592619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hankins JS, Ware RE, Rogers ZR, et al, &ldquo;Long-Term Hydroxyurea Therapy for Infants With Sickle Cell Anemia: The HUSOFT Extension Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(7):2269-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/16172253/pubmed\" id=\"16172253\" target=\"_blank\">",
"        16172253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrison CN, Campbell PJ, Buck G, et al, &ldquo;Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(1):33-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/16000354/pubmed\" id=\"16000354\" target=\"_blank\">",
"        16000354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeney MM, Whorton MR, Howard TA, et al, &ldquo;Chemical and Functional Analysis of Hydroxyurea Oral Solutions,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2004, 26(3):179-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/15125610/pubmed\" id=\"15125610\" target=\"_blank\">",
"        15125610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howard LW and Kennedy LD, &ldquo;Hydroxyurea in the Treatment of Sickle-Cell Anemia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(11):1393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/9391697/pubmed\" id=\"9391697\" target=\"_blank\">",
"        9391697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kinney TR, Helms RW, O&rsquo;Branski EE, et al, &ldquo;Safety of Hydroxyurea in Children With Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1999, 94(5):1550-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/10477679/pubmed\" id=\"10477679\" target=\"_blank\">",
"        10477679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klion AD, Bochner BS, Gleich GJ, et al, &ldquo;Approaches to the Treatment of Hypereosinophilic Syndromes: A Workshop Summary Report,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2006, 117(6):1292-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/16750989/pubmed\" id=\"16750989\" target=\"_blank\">",
"        16750989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar B, Saraswat A, and Kaur I, &ldquo;Rediscovering Hydroxyurea: Its Role in Recalcitrant Psoriasis,&rdquo;",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 2001, 40(8):530-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/11703528/pubmed\" id=\"11703528\" target=\"_blank\">",
"        11703528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Longhurst HJ, and Pinching AJ, &ldquo;Pancreatitis Associated With Hydroxyurea in Combination With Didanosine,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 2001, 322(7278):81.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGann PT, Flanagan JM, Howard TA, et al, &ldquo;Genotoxicity Associated With Hydroxyurea Exposure in Infants With Sickle Cell Anemia: Results from the BABY-HUG Phase III Clinical Trial,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2012, 59(2):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/22012708/pubmed\" id=\"22012708\" target=\"_blank\">",
"        22012708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maier-Redelsperger M, de Montalembert M, Flahault A, et al, &ldquo;Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients. The French Study Group on Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 91(12):4472-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/9616141/pubmed\" id=\"9616141\" target=\"_blank\">",
"        9616141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newton HB, Slivka MA, and Stevens C, &ldquo;Hydroxyurea Chemotherapy for Unresectable or Residual Meningioma,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 2000, 49(2):165-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/11206012/pubmed\" id=\"11206012\" target=\"_blank\">",
"        11206012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogbogu PU, Bochner BS, Butterfield JH, et al, &ldquo;Hypereosinophilic Syndrome: A Multicenter, Retrospective Analysis of Clinical Characteristics and Response to Therapy,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2009, 124(6):1319-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/19910029/pubmed\" id=\"19910029\" target=\"_blank\">",
"        19910029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Restituto P, Mugueta C, Alegre E, et al, &ldquo;Analytical Interference of Hydroxyurea in the Determination of Urea, Uric Acid, and Lactic Acid,&rdquo;",
"      <i>",
"       Anal Biochem",
"      </i>",
"      , 2006, 357(1):147-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/16843426/pubmed\" id=\"16843426\" target=\"_blank\">",
"        16843426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose PG, Ali S, Watkins E, et al, &ldquo;Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(19):2804-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/17502627/pubmed\" id=\"17502627\" target=\"_blank\">",
"        17502627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenthal MA, Ashley DL, and Cher L. &ldquo;Treatment of High Risk or Recurrent Meningiomas With Hydroxyurea,&rdquo;",
"      <i>",
"       J Clin Neurosci",
"      </i>",
"      , 2002, 9(2):156-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/11922703/pubmed\" id=\"11922703\" target=\"_blank\">",
"        11922703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thornburg CD, Dixon N, Burgett S, et al, &ldquo;A Pilot Study of Hydroxyurea to Prevent Chronic Organ Damage in Young Children With Sickle Cell Anemia,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 52(5):609-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/19061213/pubmed\" id=\"19061213\" target=\"_blank\">",
"        19061213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thornburg CD, Files BA, Luo Z, et al, &ldquo;Impact of Hydroxyurea on Clinical Events in the BABY HUG Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 120(22):4304-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/22915643/pubmed\" id=\"22915643\" target=\"_blank\">",
"        22915643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang WC, Ware RE, Miller ST, et al, &ldquo;Hydroxycarbamide in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BABY HUG),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 377(9778):1663-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/21571150/pubmed\" id=\"21571150\" target=\"_blank\">",
"        21571150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang WC, Wynn LW, Rogers ZR, et al, &ldquo;A Two-Year Pilot Trial of Hydroxyurea in Very Young Children With Sickle Cell Anemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(6):790-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/11743503/pubmed\" id=\"11743503\" target=\"_blank\">",
"        11743503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ware RE, Despotovic JM, Mortier NA, et al, &ldquo;Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children With Sickle Cell Anemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(18):4985-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/21876119/pubmed\" id=\"21876119\" target=\"_blank\">",
"        21876119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yan JH, Ataga K, Kaul S, et al, &ldquo;The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(4):434-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/15778424/pubmed\" id=\"15778424\" target=\"_blank\">",
"        15778424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimmerman SA, Schultz WH, Davis JS, et al, &ldquo;Sustained Long-Term Hematologic Efficacy of Hydroxyurea at Maximum Tolerated Dose in Children With Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(6):2039-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/16/16648/abstract-text/14630791/pubmed\" id=\"14630791\" target=\"_blank\">",
"        14630791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8543 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16648=[""].join("\n");
var outline_f16_16_16648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708910\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181021\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181022\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181060\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181025\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181043\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181026\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181027\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528419\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15598381\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180998\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180983\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181002\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181001\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181057\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181070\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181058\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181005\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180987\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299494\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180992\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180994\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181009\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181032\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2527156\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3518430\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181008\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180996\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181010\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180986\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181004\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=related_link\">",
"      Hydroxyurea: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/53/25431?source=related_link\">",
"      Hydroxyurea: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_16_16649="Membranous Light";
var content_f16_16_16649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of membranous nephropathy, showing diffuse thickening of the glomerular basement membrane (long arrows) with essentially normal cellularity. Note how the thickness of the glomerular capillary walls is much greater than that of the adjacent tubular basement membranes (short arrow). There are also areas of mesangial expansion (asterisks). Immunofluorescence microscopy (showing granular IgG deposition) and electron microscopy (showing subepithelial deposits) are generally required to confirm the diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16649=[""].join("\n");
var outline_f16_16_16649=null;
var title_f16_16_16650="Screening and early detection of melanoma";
var content_f16_16_16650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening and early detection of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Alan C Geller, RN, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Susan Swetter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/16/16650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/16/16650/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/16/16650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of melanoma of the skin, the most commonly fatal form of skin cancer, is increasing faster than any other potentially preventable cancer in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/1\">",
"     1",
"    </a>",
"    ]. Estimates for 2013 are that 76,690 invasive melanomas will be diagnosed in the United States and that melanoma could claim 9480 lives [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/2\">",
"     2",
"    </a>",
"    ]. Melanoma is the fifth most common cancer in men and seventh in women in the United States. Worldwide trends are discussed below. (See",
"    <a class=\"local\" href=\"#H112153706\">",
"     'International trends'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Five-year survival rates for people with melanoma depend upon the stage of the disease at the time of diagnosis. Survival rates decline steadily as the tumor thickness and disease stage increase. Most people with thin stage I lesions can expect prolonged disease-free survival and even cure, while those with thicker, later stage lesions (eg, &gt;2.0 mm) are more likely to die from metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Prognostic factors affecting staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A screening examination for skin lesions by a qualified observer takes only a few minutes and can uncover melanomas on the back and posterior legs, areas not easily viewed by the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Because randomized trials have not been conducted, we do not have direct evidence that screening leads to a decrease in mortality or morbidity related to melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the focus of this discussion is on melanoma, skin examination can also detect basal cell and squamous cell carcinomas that require excision, although their prognosis is more favorable than melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for melanoma refers to the routine examination of asymptomatic individuals to identify suspicious lesions that then require further evaluation to establish a diagnosis. The medical literature regarding melanoma screening is complicated by differing types of screening, differing target populations, and variations in components of services considered to be &ldquo;screening.&rdquo; Screening can be directed at all individuals or targeted to those with specific risk factors. Screening for melanoma can be performed by a variety of examiners in different settings (eg, the patient or family member, a trained health professional at a health fair, a primary care clinician during routine office visits, or a dermatologist). Some studies and discussions of &ldquo;screening&rdquo; for melanoma have also included forms of early detection (examination of patients with some concern about a skin lesion) and have incorporated patient education programs in addition to screening [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will focus primarily on screening in the context of a clinical examination by a primary care clinician. The topic will review the rationale for screening by skin examination, evidence related to the effectiveness of screening, and recommendations by expert groups. Techniques of skin examination, clinical features of melanoma, risk factors for melanoma and staging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link\">",
"     \"Skin examination and clinical features of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18038394\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and risk factors for melanoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112153699\">",
"    <span class=\"h2\">",
"     United States data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated lifetime risk of developing invasive melanoma for a person living in the United States has been dramatically increasing; lifetime risk for a person born in 1935 was estimated at 1 in 1500 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/8\">",
"     8",
"    </a>",
"    ] compared to 2010 risk estimates of 1 in 39 for Caucasian men and 1 in 58 for Caucasian women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/9\">",
"     9",
"    </a>",
"    ]. Incidence per year has increased by an estimated 3.1 percent from 1992 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/10\">",
"     10",
"    </a>",
"    ]. Incidence rates are increasing most rapidly in older individuals, doubling during a 25 year period (1983 to 2007) for men aged 60 to 64 and quadrupling for men aged 75 to 79 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/11\">",
"     11",
"    </a>",
"    ]. Although there is an overall trend toward increased diagnosis of earlier stage melanomas, the incidence of thicker melanomas has been increasing for men over age 65.",
"   </p>",
"   <p>",
"    The increase in incidence has been attributed in part to several nonbiological factors: an increase in rates of screening, with detection of thinner more indolent lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/12\">",
"     12",
"    </a>",
"    ]; an increase in the number of skin biopsies; and changes in the histologic interpretation of early evolving lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/13\">",
"     13",
"    </a>",
"    ]. However, a study of data from the US Surveillance Epidemiology and End Result (SEER, 1992-2004) from non-Hispanic white individuals found that the increased incidence of melanoma included all thicknesses of tumor and spanned all socioeconomic levels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/10\">",
"     10",
"    </a>",
"    ]. The highest increase in melanoma was among individuals of low socioeconomic status, who are less likely to have access to screening services. These results suggest that the observed increase in melanoma diagnosis is not solely attributable to screening.",
"   </p>",
"   <p>",
"    Overall mortality from melanoma has remained stable or continues to rise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/4\">",
"     4",
"    </a>",
"    ]. From 1969 through 1999, mortality declined among men and women aged 20 to 44 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. However, the mortality rate among men over age 65, who comprise 36 percent of all deaths and 20 percent of all cases, rose by 157 percent during the same period. It is estimated that 9480 individuals in the United States will have died from melanoma in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/2\">",
"     2",
"    </a>",
"    ]. On an individual basis, a man's lifetime risk of dying from melanoma is 0.36 percent, compared to 0.21 percent for women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112153706\">",
"    <span class=\"h2\">",
"     International trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of melanoma in people of European descent has also increased worldwide. Incidence rates in central Europe were similar to those in the United States between 1970 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/15\">",
"     15",
"    </a>",
"    ]. In France, the incidence rate per annum between 1980 and 2005 increased by 3.1 percent in men and 2.25 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/16\">",
"     16",
"    </a>",
"    ]. Population-based data from Manitoba, Canada, during the past 50 years indicate an ongoing increase in the annual percent change in melanoma incidence for older men and women (aged 60 to 79 years, and &ge;80 years) and a slightly decreasing rate for individuals 40 years and younger [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/17\">",
"     17",
"    </a>",
"    ]. In Australia and New Zealand, where incidence rates are the highest in the world (40 to 60 cases per 100,000 inhabitants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/15\">",
"     15",
"    </a>",
"    ]), melanoma incidence has nearly doubled every 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Melanoma survival rates are higher in Australia, the United States, and Sweden (over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]) than in Eastern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/19\">",
"     19",
"    </a>",
"    ]. In Croatia, the incidence of melanoma has risen more than 300 percent in the past 40 years, affecting men and women equally [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112154278\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for developing melanoma are both environmental and genetic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial &mdash; Approximately 10 percent of melanomas are familial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/21\">",
"       21",
"      </a>",
"      ], with considerable genetic heterogeneity among different families suggesting involvement of multiple genes. The genetic aspects of melanoma are described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"       \"Inherited susceptibility to melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atypical nevi &mdash; Individuals with atypical nevi have an associated 3- to 20-fold elevated risk of developing malignant melanoma compared to the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. Approximately 10 to 20 percent of diagnosed melanomas arise within atypical nevi [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High nevus count &mdash; There is a strong association between high nevus counts (more than 25) and melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/22\">",
"       22",
"      </a>",
"      ]. In particular, high nevus counts were more strongly associated with melanoma developing on the legs or trunk, compared to other sites [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sun or ultraviolet exposure &mdash; Clinical and epidemiologic evidence demonstrate higher rates of melanoma in people with extensive or repeated intense exposure to sunlight. A systematic review of case control studies found the strongest association for intermittent exposure and sunburn in adolescence or childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/27\">",
"       27",
"      </a>",
"      ]. Melanoma risk is also increased by ultraviolet exposure from tanning beds, especially with use before the age of 35 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phenotypic traits &mdash; Light skin pigmentation, hair color (red or blond), high-density freckling, and light eye color (green, hazel, blue) are associated with increased risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to known risk factors for the incidence of melanoma, socioeconomic factors may influence disease outcomes since less affluent groups have more advanced disease and poorer survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Although the incidence of melanoma is lower in black patients, five-year relative survival for blacks with melanoma was 74.1 percent, compared with 92.9 percent for whites; delayed diagnosis in blacks may be related both to perceived lower risk and to atypical locations of melanoma in non-sun exposed areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition to being less readily detectable, there is evidence that non-sun exposed melanomas are less responsive to available treatments due to differences in tumor biology between melanomas in non-sun exposed and sun-exposed areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473013#H100473013\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Kit inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18038601\">",
"    <span class=\"h3\">",
"     Tools for ascertaining risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk assessment aids have been developed to identify individuals who are at high risk for melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/33-37\">",
"     33-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One model was developed using data from a case-control study of 718 non-Hispanic white patients and 945 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/33\">",
"       33",
"      </a>",
"      ]. The model was designed for primary care clinicians, utilizing readily-ascertainable data. The tool involves inspection of the back for moles and asking two questions about complexion type and history of sun exposure (history of blistering sunburn in men, extent of tanning with sun exposure in women). Mild freckling and light complexion were risk factors for both men and women; more than 17 small moles and &ge;2 large moles (men) or &ge;12 small moles (women) on the back were also significant risk factors.",
"      <br/>",
"      <br/>",
"      These data were used to develop the Melanoma Risk Assessment Tool (MRAT), which is available online through the National Cancer Institute (",
"      <a class=\"external\" href=\"file://www.cancer.gov/melanomarisktool/\">",
"       file://www.cancer.gov/melanomarisktool/",
"      </a>",
"      ). The tool calculates absolute risk of melanoma over the next five years up to age 70. It is not intended for individuals with a family history of melanoma.",
"     </li>",
"     <li>",
"      Another risk assessment tool involves a survey to be completed by patients prior to a clinical encounter and assesses patient awareness of freckling, moles, and atypical nevi [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/34\">",
"       34",
"      </a>",
"      ]. Fair concordance was found between the patient&rsquo;s report and the clinical skin examination, suggesting that such a survey could be helpful in identifying patients at increased risk. Many of these high-risk patients were unaware of their risk status before completing the survey.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155905\">",
"    <span class=\"h1\">",
"     MELANOMA CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major subtypes of invasive cutaneous melanoma: superficial spreading, lentigo maligna, acral lentiginous, and nodular melanoma (",
"    <a class=\"graphic graphic_table graphicRef57168 \" href=\"UTD.htm?9/0/9228\">",
"     table 1",
"    </a>",
"    ). Although histologic subtype does not directly correlate with clinical behavior, subclassification is important for histopathologic recognition and diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathologic characteristics of melanoma\", section on 'Major subtypes of invasive melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most malignant melanomas arise as superficial indolent tumors that are confined to the epidermis, where they remain for several years. During this stage, known as the horizontal or \"radial\" growth phase, the melanoma is almost always curable by surgical excision alone. While some superficially invasive malignant melanomas (termed \"microinvasive radial growth phase\" melanomas) remain highly curable with excision alone, those that infiltrate deep into the dermis are considered to be in a \"vertical\" growth phase and have metastatic potential. Vertical growth phase melanomas can arise de novo or from a radial growth phase melanoma. It may take decades for some melanomas to reach vertical growth phase, while others develop an early vertical growth phase. Nodular melanomas have no identifiable radial growth phase and enter the vertical growth phase almost from their inception. The probability of metastases with invasive, vertical growth phase melanoma may be predicted by measuring the depth of invasion of the vertical growth phase nodule below the granular cell layer of the overlying epidermis.",
"   </p>",
"   <p>",
"    Of the major histopathologic subtypes, nodular melanoma is most difficult to diagnose at an early stage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. While the great majority of superficial spreading melanomas and lentigo maligna melanomas are diagnosed at less than 2 mm, at least half of all nodular melanomas are greater than 2 mm. Conversely, an estimated 50 percent of melanomas greater than 2 mm are nodular, although the subtype accounts for only 10 percent of invasive melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/40\">",
"     40",
"    </a>",
"    ]. Analysis of SEER registry data from 1978 to 2007 has shown that while nodular melanoma accounts for only 14 percent of incident melanomas, it comprises 37 percent of ultimately fatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89289581\">",
"    <span class=\"h1\">",
"     SCREENING RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;At first glance, it might seem that the decision to screen for melanoma would be straightforward. Patients who have melanoma detected at an earlier stage (thinner tumor) have improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/42\">",
"     42",
"    </a>",
"    ]. Cutaneous melanoma is usually visible on the skin, the examination itself is safe and well tolerated by patients, and risk factors are readily identifiable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, whether or not to screen should depend on whether screening results in decreased morbidity or mortality, comparing similar populations who have and have not undergone screening, ideally within the context of a randomized trial. Such data are not available for melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/7\">",
"     7",
"    </a>",
"    ]. In the absence of data from randomized trials demonstrating that screening decreases melanoma mortality, conclusions based on observational studies are subject to a number of potential biases (lead time bias, length bias, overdiagnosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link&amp;anchor=H18#H18\">",
"     \"Evidence-based approach to prevention\", section on 'Special screening biases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effectiveness of screening depends upon multiple factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether the clinician performing the examination can identify early stage disease",
"     </li>",
"     <li>",
"      Whether the pathologist can accurately diagnose and histologically stage the disease",
"     </li>",
"     <li>",
"      Whether the tumor is identified at a stage where treatment would be effective",
"     </li>",
"     <li>",
"      Whether the tumor identified by screening would become clinically meaningful to the patient in his or her lifetime. Identifying a disease that would not impact a person&rsquo;s quality or duration of life is referred to as &ldquo;overdiagnosis.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all biological and clinical aspects of melanoma make it conducive to screening, particularly for the nodular melanoma subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/5,43-45\">",
"     5,43-45",
"    </a>",
"    ]. Aspects of melanoma that may negatively impact screening include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some melanomas may be clinically unrecognizable, reducing the sensitivity of skin examination.",
"     </li>",
"     <li>",
"      The detectable preinvasive phase may be absent (eg, nodular melanoma) or too short in duration for detection by periodic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons not to screen for melanoma, in the absence of definitive evidence regarding effectiveness, are the potential to generate unnecessary skin biopsies with correlates of anxiety, scarring, and expense; as well as &ldquo;opportunity costs.&rdquo; The latter refer to the recognition that a clinician&rsquo;s time with a patient is not limitless and is best spent doing those things that provide the greatest benefit. If skin examination precluded time for cervical cancer screening, for example, there would be lost opportunity to do something of known effectiveness. Assessing risk for skin cancer through a few simple questions (eg, history of sunburns, changing moles, family history) can help the clinician make more effective use of the routine visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3874830\">",
"    <span class=\"h1\">",
"     SCREENING EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician examination for skin cancer and ascertainment of risk factors can be carried out in tandem, taking only a few minutes, with a source of bright light and a magnifying lens. Melanomas can occur anywhere on the skin surface but are frequently located on the back and other areas that may be easy to miss with self-inspection. The following material is a brief discussion of the skin examination; a detailed discussion is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link\">",
"     \"Skin examination and clinical features of melanoma\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Photographs of typical melanomas are shown in pictures 1 to 4 (",
"    <a class=\"graphic graphic_picture graphicRef57466 \" href=\"UTD.htm?28/40/29326\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78826 \" href=\"UTD.htm?0/3/54\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80955 \" href=\"UTD.htm?29/25/30110\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62105 \" href=\"UTD.htm?4/54/4967\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3874837\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The A, B, C, D, Es of melanoma recognition are valuable for patient education and for all clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymmetry",
"     </li>",
"     <li>",
"      Border irregularities",
"     </li>",
"     <li>",
"      Color variegation (ie, different colors within the same region)",
"     </li>",
"     <li>",
"      Diameter greater than 6 mm",
"     </li>",
"     <li>",
"      Enlargement or evolution of color change, shape, or symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A seven point checklist was designed in England and is another tool for the early detection of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/47\">",
"     47",
"    </a>",
"    ]. The checklist includes three major and four minor features. Major features are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Change in size",
"     </li>",
"     <li>",
"      Change in color",
"     </li>",
"     <li>",
"      Change in shape",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor features are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammation",
"     </li>",
"     <li>",
"      Bleeding or crusting",
"     </li>",
"     <li>",
"      Sensory change",
"     </li>",
"     <li>",
"      Lesion diameter greater than 6 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These checklists were designed particularly for use by the lay public to indicate when a skin lesion should be evaluated by a clinician, but clinicians also may find the guides useful. Any one of the individual points should alert the individual to seek professional advice or the clinician to further evaluate the lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link&amp;anchor=H81531898#H81531898\">",
"     \"Skin examination and clinical features of melanoma\", section on 'Management of patients with suspicious skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3874500\">",
"    <span class=\"h2\">",
"     Skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening examination of the total skin surface can increase the likelihood of detecting melanoma six-fold compared with partial examination. Men have more lesions on the back and women on their lower legs since these are common areas of sunburn and sun exposure; screening of those sites could particularly aid early detection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Effectiveness of screening and early detection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sensitivity, specificity, and predictive value of the skin examination differs according to the screener and the type of population screened [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/49\">",
"     49",
"    </a>",
"    ]. Some studies have documented the accuracy of dermatologists in diagnosing melanoma in the clinical setting, although few data are available to evaluate the visual examination in the screening setting.",
"   </p>",
"   <p>",
"    Few medical professionals have specific education in early detection of melanoma. Dermatologists are the most well-trained and are significantly better than nondermatologist physicians at diagnosing melanoma and nonmelanoma skin cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/50\">",
"     50",
"    </a>",
"    ], although the thickness of melanomas detected by dermatologists versus non-dermatologist physicians do not appear to substantially differ. However, integration of the skin examination into a routine physical assessment by primary care providers may be the most practical and comprehensive strategy for reducing skin cancer morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/49\">",
"     49",
"    </a>",
"    ]. In one study in France, general practitioner participation in continuing medical education for skin cancer detection was associated with increased detection of melanomas with a lower Breslow thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/51\">",
"     51",
"    </a>",
"    ]. INFORMED (INternet curriculum FOR Melanoma Early Detection) is a web-based educational training program for primary care clinicians to improve skin cancer detection, available for widespread use at",
"    <span class=\"nowrap\">",
"     file://www.skinsight.com/info/forprofessionals",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermoscopy (or epiluminescence microscopy [ELM]) refers to the use of a hand-held lens in combination with oil immersion to better view a pigmented lesion. This technique, largely performed by dermatologists, is of value in improving melanoma detection. A meta-analysis concluded that although dermoscopy performed by skilled practitioners improved diagnostic accuracy, its use by untrained or less-experienced examiners was no better than clinical inspection without dermoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/54\">",
"     54",
"    </a>",
"    ]. Biopsy is still necessary when there is a sufficient index of suspicion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF SCREENING AND EARLY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have established the efficacy of clinician screening for melanoma. It has been estimated that a randomized trial in the United States would require approximately 800,000 participants for adequate power to determine if screening impacts mortality, due to the relatively low melanoma mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictions of the mortality impact and cost-effectiveness of melanoma screening vary in the absence of randomized trial data. Since the prognosis of melanoma is related to its thickness and screening detects melanomas that are thinner than those detected outside of screening, many believe that screening will decrease melanoma mortality. However, one case-control study found no significant association between self reported skin examination by either patient or clinician and death from melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/56\">",
"     56",
"    </a>",
"    ]. In another study, melanoma mortality decreased five years after a statewide population-based physician screening program was initiated (and did not decrease in geographic areas not offered the screening), although the lack of a randomized trial does not allow definitive conclusions about the impact of screening on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Models have been developed based upon the prevalence of melanoma and the predicted impact of detecting early stage disease. One cost-effectiveness model of screening examinations performed by a dermatologist suggested that screening for melanoma is reasonably cost-effective compared with other cancer screening strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/58\">",
"     58",
"    </a>",
"    ]. Another analysis, based upon computer simulation, suggested that one-time melanoma screening for the general United States population over 50 years of age and biannual (every two years) screening for first degree relatives of melanoma patients would be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155960\">",
"    <span class=\"h2\">",
"     Clinician detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large population-based screening program in an area in northern Germany, the Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany project (the SCREEN project), has reported results with five-year follow-up data [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/57,60\">",
"     57,60",
"    </a>",
"    ]. A randomized trial could not be conducted for lack of federal support. In its place, screening was offered for one year (2003 to 2004) to 1.9 million insured citizens aged 20 years and older living in Schleswig-Holstein and 360,000 individuals participated. Participants chose either to be screened by a nondermatologist trained in skin examination (77 percent) or by a dermatologist directly; nearly 16,000 biopsies were performed and 585 melanomas were identified. Overall, one in 23 screenees had an excisional skin biopsy; 620 persons needed to be screened to detect one melanoma. As expected the incidence of melanoma increased during the screening period (16 percent higher in men and 38 percent higher in women compared to two years earlier) and returned to preprogram levels when the program was stopped. Ninety percent of the melanomas detected by screening were less than 1 mm thick. The positivity rate of biopsies for melanoma was 5 percent in men &gt;65 years and &lt;2 percent in men 20 to 49 years. This observational study demonstrated that mortality from melanoma in 2008 was nearly 50 percent lower in both men and women from Schleswig-Holstein than in the rest of Germany and substantially lower than expected based on historical rates for this area (per 100,000 men, melanoma mortality was 0.79 [95% CI 0.47-1.22] for the screened area and 1.75 [CI 1.65-1.85] for the non-screened area; per 100,000 women, melanoma mortality was 0.66 [CI 0.37-1.07] for the screened area and 1.13 [CI 1.05-1.21] for the non-screened area). Germany initiated a nationwide program to screen adults 35 years and older every two years for the early detection of skin cancer in 2008.",
"   </p>",
"   <p>",
"    Prior to the German project, a randomized trial of population screening was planned and partially implemented in Australia, where the rate of melanoma is higher than in most other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/61\">",
"     61",
"    </a>",
"    ]. The trial included three components: (1) community education to provide information about melanoma and screening; (2) education and support for medical practitioners to improve clinician skills; and (3) free skin screening services. The study design called for randomizing 44 Queensland communities, but the trial was initiated in only 18 towns (9 intervention and 9 control) and was not completed due to lack of funding.",
"   </p>",
"   <p>",
"    Rates of performance of the whole-body skin cancer examination were measured by surveys of residents in intervention and control towns [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Baseline screening rates were similar in intervention and control towns (11.2 and 11.3 percent, respectively). At two years, screening rates rose to 35 percent in intervention towns compared to 14 percent in control communities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/63\">",
"     63",
"    </a>",
"    ]. More than 16,000 whole-body examinations were performed by general practitioners and special screening services, with skin cancer detected in 2.4 percent (33 melanomas, 259 basal cell carcinomas, and 97 squamous cell carcinomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/64\">",
"     64",
"    </a>",
"    ]. The overall specificity of the skin examination for melanoma was 86 percent. Although the trial was not completed and it will not be possible to determine the impact of screening on mortality from these data, the trial demonstrated the acceptability and feasibility of a community-based screening program for melanoma.",
"   </p>",
"   <p>",
"    Multiple studies have consistently shown that melanomas detected by clinicians in the course of a skin examination are thinner than those found by patients or their significant others [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/16,65-72\">",
"     16,65-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based case-control study in Queensland, Australia, patients who reported having a full skin examination by a physician during the three years preceding a diagnosis of melanoma, compared with those who had not had an examination, had a 14 percent lower risk for a lesion &gt;0.75 mm thick (OR 0.86, 95% CI 0.75-0.98) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/68\">",
"       68",
"      </a>",
"      ]. The decrease in risk was greatest for the thickest melanomas (risk reduction 40 percent for lesions &ge;3 mm). This case control study represents the strongest evidence supporting screening in the setting of primary care.",
"     </li>",
"     <li>",
"      In a study of 566 adults with invasive melanoma who were surveyed within three months of diagnosis, thinner (&le;1 mm, T1) tumors were associated with physician discovery. While only 19 percent of patients reported physician detection of their melanoma, full-body physician skin examination (PSE) within the year prior to diagnosis was associated with thinner tumors (OR, 2.51; 95% CI, 1.62-3.87), largely due to the effect of PSE in men &gt;60 years, who had four times the odds of a thinner melanoma (OR 4.09, 95% CI, 1.88-8.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multivariate analysis of 816 melanoma patients, detection by a dermatologist was the strongest predictor of melanoma less than 1 mm in thickness (OR 0.45, 95% CI 0.28-0.73) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of nine studies in which data regarding tumor thickness and the initial detection of melanoma were available, benefit in terms of thickness for tumors detected by physician diagnosis was demonstrated in each study [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/71\">",
"       71",
"      </a>",
"      ]. In the cumulative review of more than 7500 patients, a mean tumor thickness difference of 0.55 mm was found when comparing lesions initially detected by physicians or by",
"      <span class=\"nowrap\">",
"       patients/significant",
"      </span>",
"      others.",
"     </li>",
"     <li>",
"      In a study using data from the Queensland Cancer Registry, when compared with patients with physician-detected nodular melanoma, patients with self-detected nodular melanoma were five times more likely to have thick melanomas (&gt;4 mm rather than &lt;1 mm) (OR 4.86, 95% CI 1.21-19.51) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/38\">",
"       38",
"      </a>",
"      ]. Individuals who had not been screened by a physician within the preceding three years also had thicker lesions than those who had received more recent complete skin examinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these data from observational studies do not necessarily translate into a mortality benefit if screening results in overdiagnosis (ie, the detection of cancers that might not cause harm over the patient&rsquo;s lifetime).",
"   </p>",
"   <p>",
"    Current detection practices in the United States have",
"    <strong>",
"     not",
"    </strong>",
"    affected rates of prognostically unfavorable tumors. Review of data from the US Surveillance Epidemiology and End Result (SEER) program from 1988 to 2006 revealed that the distribution of thickness of tumors over the 19 year period was stable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/74\">",
"     74",
"    </a>",
"    ]. However, among those melanomas resulting in death, the proportion of thick tumors had increased. In another report, also based upon SEER data (1986 to 2001), there was a 2.5 fold increase in skin biopsy rate among patients aged 65 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/13\">",
"     13",
"    </a>",
"    ]. The extra biopsies resulted in detection of in situ and local melanoma but did not increase the detection of advanced melanoma; melanoma mortality rates remained stable during the reporting period, suggesting overdiagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155400\">",
"    <span class=\"h2\">",
"     Self-examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of skin self-examination for suspicious lesions is intuitive. However, the prevalence of this practice is generally low, even in high-risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/75\">",
"     75",
"    </a>",
"    ]. A few studies have associated the practice of skin self-examination with the detection of thinner tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/69,76\">",
"     69,76",
"    </a>",
"    ]. In a case-control study, self-screening, practiced by only 15 percent of subjects, suggested a reduced risk of advanced melanoma among melanoma patients (OR 0.58, 95% 0.31-1.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/77\">",
"     77",
"    </a>",
"    ]. In a follow-up of this study population at a median of 5.4 years, excluding patients who were diagnosed with metastatic disease or lentigo maligna melanoma, reported skin self-examination and physician skin examination were not statistically significantly associated with risk of death from melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/56\">",
"     56",
"    </a>",
"    ]. This case-control study remains the major published investigation on self-examination in the United States.",
"   </p>",
"   <p>",
"    A study of 120 individuals at greatly increased risk of melanoma found that only 50 percent of participants had performed self-examination at least four times in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/78\">",
"     78",
"    </a>",
"    ]. Rates of performance of self-examination may be increased by programs that involve computer-assisted patient education, hands-on tutorials, and telecommunication reminders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159434\">",
"    <span class=\"h1\">",
"     SCREENING IN HIGHER RISK GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339581723\">",
"    <span class=\"h2\">",
"     Targeted populations by age and sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be particular value in screening those populations of patients at risk for advanced disease and death from melanoma, including middle-aged and older white men and possibly those of lower socioeconomic status. Almost one-half (46 percent) of all United States melanoma deaths occur in men ages 50 years and over, with similar mortality trends noted in New Zealand, Australia, and the United Kingdom (particularly West Scotland) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/5,80\">",
"     5,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the American Academy of Dermatology demonstrate the highest yield of screening for melanoma in men 50 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/81\">",
"     81",
"    </a>",
"    ]. Older men accounted for 44 percent of confirmed melanomas but represented only 25 percent of those screened. Similarly, in the partially-implemented randomized controlled trial of screening for melanoma in Australia, men &gt;50 years accounted for 49 percent of melanoma cases but only 21 percent of attendees [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/82\">",
"     82",
"    </a>",
"    ]. Melanomas detected in men during a routine clinician exam are thinner than those detected by the patient or his partner [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/65,66,73\">",
"     65,66,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poorer survival for men with melanoma, compared to women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/83\">",
"     83",
"    </a>",
"    ], may be explained both by differences in tumor biology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/84\">",
"     84",
"    </a>",
"    ] and by gender differences in skin awareness, self-examination, and other early detection practices. Two studies found that men discovered their own melanomas less frequently than women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/67,85\">",
"     67,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339582288\">",
"    <span class=\"h2\">",
"     High-risk individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;A precedent for screening high-risk patients has evolved by monitoring and educating persons with multiple nevi or atypical moles within the familial melanoma setting. Surveillance and education of family members of melanoma patients in Philadelphia, the Netherlands, and Sweden led to the detection of thinner melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/5,86\">",
"     5,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for the development of melanoma\", section on 'Atypical nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there have been no randomized trials of screening in high-risk populations, several expert groups endorse recommendations that patients at high risk of developing melanoma should be educated regarding the need for regular physician examinations, skin self-examination, and sun protection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The Melanoma Genetics Consortium recommends that members of high-risk families have a baseline skin examination by a trained health care provider beginning at the age of 10, with follow-up every six months until the nevus pattern is stable and the patient is judged competent at self-surveillance, and then annual follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/87\">",
"     87",
"    </a>",
"    ]. The Australian Cancer Network recommends monthly skin self-examination and biannual full body skin examination by a clinician for high-risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253014520\">",
"    <span class=\"h3\">",
"     Genetic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominantly inherited mutations in melanoma susceptibility genes are responsible for only 5 to 10 percent of cutaneous melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/89\">",
"     89",
"    </a>",
"    ]. Mutations in two genes, CDKN2A and CDK4, have been identified in melanoma-prone families [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Features associated with the presence of familial melanoma include multiple cases of cutaneous melanoma on the same side of the family, multiple primary cutaneous melanomas in the same individual, early age of onset of cutaneous melanoma, and multiple nevi. Mutations are found in approximately 15 percent of patients with multiple primary melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Melanoma Genetics Consortium recommends that DNA testing for mutations in melanoma susceptibility genes be performed only",
"    <strong>",
"     rarely",
"    </strong>",
"    outside of defined research programs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/87,92\">",
"     87,92",
"    </a>",
"    ]. This recommendation is based upon a lack of knowledge regarding the penetrance of CDKN2A mutations, the failure to identify mutations in more than 60 percent of hereditary melanoma kindreds, and limited data on the efficacy of prevention and surveillance strategies. Similar recommendations have been made by the American Society of Clinical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic risk factors for melanoma and the role of genetic screening are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18037807\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of formal randomized trials, current screening recommendations are diverse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Cancer Society Guidelines for the Early Detection of Cancer recommend skin examination as part of the broader cancer-related checkup. These general guidelines state: &ldquo;For people aged 20 or older having periodic health exams, a cancer-related check-up should include health counseling and, depending on a person's age and gender, exams for cancers of the thyroid, oral cavity, skin, lymph nodes, testes, and ovaries&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/95\">",
"       95",
"      </a>",
"      ]. The American Cancer Society indicated in 2010 that updated guidelines related to skin cancer screening are in preparation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Institute of Medicine concluded that \"clinicians and patients should continue to be alert to the common signs of skin cancer with a particular emphasis on older white males and on melanoma\" [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2009 update from the United States Preventive Services Task Force (USPSTF) found insufficient evidence to recommend for or against either routine screening of the general population for skin cancer by primary care providers or counseling patients to perform periodic skin self-examinations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/98,99\">",
"       98,99",
"      </a>",
"      ]. The Task Force did recommend that clinicians \"remain alert\" for skin lesions with malignant features when performing a physical examination for other purposes, particularly in high-risk individuals. The USPSTF did not examine the outcomes related to surveillance of patients with higher melanoma risk or familial syndromes, such as familial atypical mole and melanoma (FAM-M) syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"       \"Inherited susceptibility to melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American Academy of Dermatology recommends that persons at highest risk (ie, those with a strong family history of melanoma and multiple clinically atypical moles), perform frequent self-examination and seek professional evaluation of the skin at least once per year [",
"      <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253014473\">",
"    <span class=\"h1\">",
"     SYNTHESIS OF FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of randomized trials, it is not certain that screening for melanoma will result in decreased mortality. Data from the German population-based study strongly suggest that skin cancer screening was associated with reduced melanoma mortality; ongoing data analysis from the implementation of this program on a national level is awaited for further confirmation of these findings. Data suggest that screening will identify early stage lesions, and it is known that prognosis is significantly better for early, compared to later, stage melanoma. The benefits of screening are the potential to treat and cure disease that, in the absence of identification by screening, would result in greater morbidity and mortality. The risks of screening are the potential that false positive findings would lead to unnecessary biopsies, and that some melanomas would lead to treatment of biologically indolent melanoma. The effectiveness of screening would be influenced by the expertise of the screening examiner and pathologist, and by the natural history of some melanomas that could not be identified at early stages.",
"   </p>",
"   <p>",
"    These concerns have led to debate, but no consensus, on whether screening for melanoma is likely to be effective in saving lives. Based upon the available evidence, and subject to revision when new data become available, we suggest that persons at higher risk for advanced melanoma (white men over 50 years) and individuals with multiple moles or a few atypical moles have a full body skin examination performed by a clinician who has had appropriate training in the identification of melanoma. Such a clinician may be either a dermatologist or a generalist who has extensive experience in skin examination or who has undergone a training program to identify suspicious skin lesions. The appropriate frequency for such examinations is uncertain. We suggest that it be at least annual in patients with increased risk due to family history or multiple atypical nevi. We also suggest that high-risk patients be educated about melanoma risk factors and appearance and be advised to routinely look at their skin and alert their physicians if they note changing moles or other suspicious skin lesions.",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    suggest routine screening for the general population outside of these risk groups. We agree with the USPSTF that clinicians remain vigilant for any suspicious lesions identified in the course of a routine or sick visit (opportunistic case finding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/101\">",
"     101",
"    </a>",
"    ]) for any patient and make appropriate referrals for further evaluation of all such lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339582723\">",
"    <span class=\"h2\">",
"     Information gaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important challenges include determining who can most effectively screen, who should be screened, where screenings should take place, and whether a major trial for population-based screening can be funded and carried out [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/5\">",
"     5",
"    </a>",
"    ]. It is unlikely that a randomized trial of melanoma screening with mortality outcome will be conducted in the near future. Without this definitive data, the risks and benefits of screening will need to be extracted from data obtained from ongoing screening programs.",
"   </p>",
"   <p>",
"    A variety of screening programs, none randomized, are being conducted in multiple countries throughout Europe and in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/85,89,102,103\">",
"     85,89,102,103",
"    </a>",
"    ]. Many programs combine education with screening, and none report mortality as an endpoint. A five-year nationwide skin cancer screening trial is ongoing in Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?16/16/16650/abstract/104\">",
"     104",
"    </a>",
"    ]. German residents ages 35 years of age and above are encouraged to receive a full skin cancer examination from their general practitioner or dermatologist. German physicians have been trained in the skin cancer examination, and more than 20 million residents have received examinations through 2012. Historical mortality rates (prior to the inception of screening) will be compared with rates during the five-year screening program to provide information about melanoma as well as other types of skin cancer.",
"   </p>",
"   <p>",
"    Future analyses of screening programs should determine the number of melanomas that occur in participants with negative findings (ie, false negative screens) and the number of negative biopsies that are generated by screening (false positive screens). The effectiveness of screening performed by dermatologists should be compared with nonspecialist screening. Cancer registries should routinely record melanoma thickness, along with subtype, ulceration, and other prognostic variables, so that melanoma parameters can be monitored over time. The impact of clinician training programs and patient educational programs on skin cancer recognition should also be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of melanoma of the skin, the most fatal form of skin cancer, is increasing faster than any other potentially preventable cancer in the United States. The mortality rate among white men over age 65, who comprise 36 percent of all deaths, more than doubled over the past 30 years. Risk factors for developing melanoma are both environmental and genetic. (See",
"      <a class=\"local\" href=\"#H18038394\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No randomized trials have established the efficacy of screening for melanoma. A prospective population-based screening project in Germany suggested a decrease in melanoma mortality rates associated with screening, although this could not be definitively attributed to screening. Although the majority of melanomas are initially detected by patients themselves, melanomas detected by physicians have consistently been shown to be thinner than those found by patients or their significant others. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effectiveness of screening and early detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The highest yield for screening is in men 50 years or older, and melanomas detected in men during a routine clinician exam are thinner than those detected by the patient or his partner. Poorer survival for men with melanoma, compared to women, may relate both to tumor biology and gender differences in skin awareness, self-examination, and physician-seeking practices. (See",
"      <a class=\"local\" href=\"#H339581723\">",
"       'Targeted populations by age and sex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients determined to be at high risk of developing melanoma, based on the presence of multiple atypical nevi or history suggesting a familial melanoma syndrome, should be educated regarding the need for regular full skin examinations by clinicians with skin expertise, skin self-examination, and sun protection. Autosomal dominantly inherited mutations in melanoma susceptibility genes are responsible for only a small proportion of cutaneous melanomas and the role of genetic screening should be limited to patients participating in a defined research program. (See",
"      <a class=\"local\" href=\"#H339582288\">",
"       'High-risk individuals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H253014520\">",
"       'Genetic screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Melanoma screening recommendations from expert groups vary, in the absence of definitive data. We suggest that persons at higher risk for melanoma (white men over 50 years, individuals with a history of significant sunburn, or multiple moles) have a periodic full body skin examination performed by a clinician who has had appropriate training in the identification of melanoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend that individuals at highest risk (history suggesting a familial melanoma syndrome or with multiple atypical nevi) have a regular full body skin examination by a clinician with skin expertise (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The optimal frequency for such examination is unknown. We also suggest that individuals at high risk for skin cancer be counseled about self-skin examination and advised to examine their skin regularly and notify their physicians if moles change. (See",
"      <a class=\"local\" href=\"#H253014473\">",
"       'Synthesis of findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without identified increased risk, we agree with the USPSTF that clinicians remain vigilant for any suspicious lesions identified in the course of a routine or sick visit (opportunistic case finding) and make appropriate referrals for further evaluation of all such lesions. (See",
"      <a class=\"local\" href=\"#H253014473\">",
"       'Synthesis of findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of Marie-France Demierre, MD, FRCPC, who passed away in April 2010. UpToDate wishes to acknowledge Dr. Demierre's past contributions to this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/1\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/3\">",
"      Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/4\">",
"      Geller AC, Miller DR, Annas GD, et al. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288:1719.",
"     </a>",
"    </li>",
"    <li>",
"     Koh HK, Geller AC, Lew RA. Melanoma. In: Cancer screening: Theory and practice, Kramer BS, Gohagan JK, Prorok PC (Eds), Marcel Dekker, New York 1999. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/6\">",
"      Curiel-Lewandrowski C, Chen SC, Swetter SM, Melanoma Prevention Working Group-Pigmented Skin Lesion Sub-Committee. Screening and prevention measures for melanoma: is there a survival advantage? Curr Oncol Rep 2012; 14:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/7\">",
"      Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/8\">",
"      Kopf AW, Rigel DS, Friedman RJ. The rising incidence and mortality rate of malignant melanoma. J Dermatol Surg Oncol 1982; 8:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/9\">",
"      Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010; 60:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/10\">",
"      Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666.",
"     </a>",
"    </li>",
"    <li>",
"     Atekruse, SF, Kosary, CL, Krapcho, M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Based on November 2009 SEER data submission, posted to the SEER website, 2010. file://seer.cancer.gov/csr/1975_2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/12\">",
"      Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch Dermatol 1996; 132:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/13\">",
"      Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331:481.",
"     </a>",
"    </li>",
"    <li>",
"     US National Center for Health Statistics (NCHS) and the Surveillance, Epidemiology, and End Results database (SEER). Available at: file://seer.cancer.gov/canques/ (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/15\">",
"      Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/16\">",
"      Durbec F, Vitry F, Granel-Brocard F, et al. The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France. Arch Dermatol 2010; 146:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/17\">",
"      Pruthi DK, Guilfoyle R, Nugent Z, et al. Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005. J Am Acad Dermatol 2009; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/18\">",
"      Whiteman DC, Valery P, McWhirter W, Green AC. Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer 1997; 70:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/19\">",
"      Buljan M, Rajaci N, Vurnek Zivkovi M, et al. Epidemiological data on melanoma from the referral centre in croatia (2002-2007). Coll Antropol 2008; 32 Suppl 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/20\">",
"      Rhodes AR, Weinstock MA, Fitzpatrick TB, et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987; 258:3146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/21\">",
"      Rivers JK. Melanoma. Lancet 1996; 347:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/22\">",
"      Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/23\">",
"      Kang S, Barnhill RL, Mihm MC Jr, et al. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994; 130:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/24\">",
"      Halpern AC, Guerry D 4th, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100:346S.",
"     </a>",
"    </li>",
"    <li>",
"     Tsao HK, Pehamberger H, Sober AJ. Precursor lesions and markers for increased risk of melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, Cutaneous Melanoma (Ed), Quality Medical Publishing Inc, St. Louis 1998. p.65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/26\">",
"      Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009; 45:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/27\">",
"      Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/28\">",
"      Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/29\">",
"      International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/30\">",
"      Geller AC, Miller DR, Lew RA, et al. Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. Am J Public Health 1996; 86:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/31\">",
"      MacKie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. BMJ 1996; 312:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/32\">",
"      Myles ZM, Buchanan N, King JB, et al. Anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998-2007. Arch Dermatol 2012; 148:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/33\">",
"      Fears TR, Guerry D 4th, Pfeiffer RM, et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006; 24:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/34\">",
"      Jackson A, Wilkinson C, Ranger M, et al. Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score. BMJ 1998; 316:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/35\">",
"      Mar V, Wolfe R, Kelly JW. Predicting melanoma risk for the Australian population. Australas J Dermatol 2011; 52:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/36\">",
"      Fortes C, Mastroeni S, Bakos L, et al. Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev 2010; 19:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/37\">",
"      Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005; 23:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/38\">",
"      Geller AC, Elwood M, Swetter SM, et al. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009; 115:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/39\">",
"      Warycha MA, Christos PJ, Mazumdar M, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008; 113:3341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/40\">",
"      Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005; 141:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/41\">",
"      Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. Arch Dermatol 2012; 148:30.",
"     </a>",
"    </li>",
"    <li>",
"     Balch CM, Soong SJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, et al (Eds), JB Lippincott Company, Philadelphia 1992. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/43\">",
"      MacKie RM. Thickness and delay in diagnosis of melanoma: how far can we go? Arch Dermatol 1999; 135:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/44\">",
"      Elwood JM. Screening for melanoma and options for its evaluation [see comment]. J Med Screen 1994; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/45\">",
"      Burton RC, Armstrong BK. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 1994; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/46\">",
"      Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004; 292:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/47\">",
"      Healsmith MF, Bourke JF, Osborne JE, Graham-Brown RA. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994; 130:48.",
"     </a>",
"    </li>",
"    <li>",
"     Langley, RG, Fitzpatrick, et al. Clinical characteristics. In: Cutaneous melanoma, Balch, CM, Houghton, AN, Sober, AJ, Soong, SJ (Eds), Quality Medical Publishing, Inc, St. Louis 1998. p.81.",
"    </li>",
"    <li>",
"     Koh, HK, Geller, et al. Melanoma. In: Cancer screening: Theory and practice, Kramer, BS, Gohagan, JK, Prorok, PC (Eds), Marcel Dekker, New York 1999. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/50\">",
"      Gerbert B, Maurer T, Berger T, et al. Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Arch Dermatol 1996; 132:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/51\">",
"      Grange F, Barbe C, Mas L, et al. The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France. Br J Dermatol 2012; 167:1351.",
"     </a>",
"    </li>",
"    <li>",
"     INFORMED: Melanoma and skin cancer early detection. file://www.skinsight.com/info/for_professionals/skin-cancer-detection-informed/skin-cancer-education (Accessed on July 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/53\">",
"      Shaikh WR, Geller A, Alexander G, et al. Developing an interactive web-based learning program on skin cancer: the learning experiences of clinical educators. J Cancer Educ 2012; 27:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/54\">",
"      Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/55\">",
"      Menzies SW, Bischof L, Talbot H, et al. The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma. Arch Dermatol 2005; 141:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/56\">",
"      Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/57\">",
"      Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/58\">",
"      Freedberg KA, Geller AC, Miller DR, et al. Screening for malignant melanoma: A cost-effectiveness analysis. J Am Acad Dermatol 1999; 41:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/59\">",
"      Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007; 143:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/60\">",
"      Waldmann A, Nolte S, Geller AC, et al. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. Arch Dermatol 2012; 148:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/61\">",
"      Lowe JB, Ball J, Lynch BM, et al. Acceptability and feasibility of a community-based screening programme for melanoma in Australia. Health Promot Int 2004; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/62\">",
"      Aitken JF, Elwood JM, Lowe JB, et al. A randomised trial of population screening for melanoma. J Med Screen 2002; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/63\">",
"      Aitken JF, Janda M, Elwood M, et al. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006; 54:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/64\">",
"      Aitken JF, Youl PH, Janda M, et al. Increase in skin cancer screening during a community-based randomized intervention trial. Int J Cancer 2006; 118:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/65\">",
"      Swetter SM, Johnson TM, Miller DR, et al. Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. Arch Dermatol 2009; 145:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/66\">",
"      Geller AC, Johnson TM, Miller DR, et al. Factors associated with physician discovery of early melanoma in middle-aged and older men. Arch Dermatol 2009; 145:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/67\">",
"      Epstein DS, Lange JR, Gruber SB, et al. Is physician detection associated with thinner melanomas? JAMA 1999; 281:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/68\">",
"      Aitken JF, Elwood M, Baade PD, et al. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 2010; 126:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/69\">",
"      Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/70\">",
"      Kantor J, Kantor DE. Routine dermatologist-performed full-body skin examination and early melanoma detection. Arch Dermatol 2009; 145:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/71\">",
"      Terushkin V, Halpern AC. Melanoma early detection. Hematol Oncol Clin North Am 2009; 23:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/72\">",
"      Kovalyshyn I, Dusza SW, Siamas K, et al. The impact of physician screening on melanoma detection. Arch Dermatol 2011; 147:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/73\">",
"      Swetter SM, Pollitt RA, Johnson TM, et al. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer 2012; 118:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/74\">",
"      Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol 2010; 130:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/75\">",
"      Aitken JF, Janda M, Lowe JB, et al. Prevalence of whole-body skin self-examination in a population at high risk for skin cancer (Australia). Cancer Causes Control 2004; 15:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/76\">",
"      Pollitt RA, Geller AC, Brooks DR, et al. Efficacy of skin self-examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev 2009; 18:3018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/77\">",
"      Berwick M, Begg CB, Fine JA, et al. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996; 88:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/78\">",
"      Kasparian NA, McLoone JK, Meiser B, et al. Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma. Br J Cancer 2010; 103:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/79\">",
"      Aneja S, Brimhall AK, Kast DR, et al. Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. Arch Dermatol 2012; 148:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/80\">",
"      Centers for Disease Control (CDC). Death rates of malignant melanoma among white men--United States, 1973-1988. MMWR Morb Mortal Wkly Rep 1992; 41:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/81\">",
"      Geller AC, Sober AJ, Zhang Z, et al. Strategies for improving melanoma education and screening for men age &gt;or= 50 years: findings from the American Academy of Dermatological National Skin Cancer Sreening Program. Cancer 2002; 95:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/82\">",
"      Janda M, Youl PH, Lowe JB, et al. What motivates men age &gt; or =50 years to participate in a screening program for melanoma? Cancer 2006; 107:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/83\">",
"      Joosse A, Collette S, Suciu S, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 2012; 30:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/84\">",
"      Demierre MF. Gender differences in melanoma. J Womens Health Gend Based Med 2000; 9:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/85\">",
"      Koh HK, Miller DR, Geller AC, et al. Who discovers melanoma? Patterns from a population-based survey. J Am Acad Dermatol 1992; 26:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/86\">",
"      Hansson J, Bergenmar M, Hofer PA, et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J Clin Oncol 2007; 25:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/87\">",
"      Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.",
"     </a>",
"    </li>",
"    <li>",
"     Australian Cancer Network. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. National Health and Medical Research Council (NHMRC), Canberra, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/89\">",
"      Florell SR, Boucher KM, Garibotti G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005; 23:7168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/90\">",
"      Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/91\">",
"      Goldstein AM, Tucker MA. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 1997; 89:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/92\">",
"      Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61:677.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/93\">",
"      Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14:1730.",
"     </a>",
"    </li>",
"    <li>",
"     Koh HK, Geller AC, Miller DR, et al. Melanoma screening and education. In: Cutaneous Melanoma, Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing, Inc, St. Louis 1998. p.573.",
"    </li>",
"    <li>",
"     American Cancer Society guidelines for the early detection of cancer. file://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer (Accessed on September 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/96\">",
"      Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010; 60:99.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. medical coverage for prevention and other services, National Academy Press, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/98\">",
"      U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:188.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to Clinical Preventive Services, 3rd ed. Available at: www.ahrq.gov/clinic/preview.htm (Accessed on July 25, 2002).",
"    </li>",
"    <li>",
"     American Academy of Dermatology and AAD Association; Melanoma fact sheet. file://www.aad.org/public/exams/screenings/documents/AAD_Melanoma_Fact_Sheet.pdf (Accessed on January 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/101\">",
"      Bigby M. Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening. Arch Dermatol 2010; 146:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/102\">",
"      Geller AC, Swetter SM, Brooks K, et al. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007; 57:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/103\">",
"      Janda M, Baade PD, Youl PH, et al. The skin awareness study: promoting thorough skin self-examination for skin cancer among men 50 years or older. Contemp Clin Trials 2010; 31:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/16/16650/abstract/104\">",
"      Geller AC, Greinert R, Sinclair C, et al. A nationwide population-based skin cancer screening in Germany: proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009). Cancer Epidemiol 2010; 34:355.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4845 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16650=[""].join("\n");
var outline_f16_16_16650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18038394\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112153699\">",
"      United States data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112153706\">",
"      International trends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112154278\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18038601\">",
"      - Tools for ascertaining risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1155905\">",
"      MELANOMA CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89289581\">",
"      SCREENING RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3874830\">",
"      SCREENING EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3874837\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3874500\">",
"      Skin examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECTIVENESS OF SCREENING AND EARLY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1155960\">",
"      Clinician detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1155400\">",
"      Self-examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159434\">",
"      SCREENING IN HIGHER RISK GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339581723\">",
"      Targeted populations by age and sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339582288\">",
"      High-risk individuals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H253014520\">",
"      - Genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18037807\">",
"      RECOMMENDATIONS OF EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H253014473\">",
"      SYNTHESIS OF FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339582723\">",
"      Information gaps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4845|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29326\" title=\"picture 1\">",
"      Superficial spreading melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/3/54\" title=\"picture 2\">",
"      Acral lentiginous melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30110\" title=\"picture 3\">",
"      Nodular melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/54/4967\" title=\"picture 4\">",
"      New lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4845|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/0/9228\" title=\"table 1\">",
"      Compare melanoma subtypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_16_16651="Differences in cervical CA relapse by histology and stage";
var content_f16_16_16651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cervical adenocarcinoma versus squamous cell cancer: Relapse rates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disease stage",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients with AdenoCA",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients with SCC",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Five-year relapse rates for AdenoCA versus SCC, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pelvic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Distant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IB1",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        706",
"       </td>",
"       <td>",
"        6 versus 3 (p&lt;0.01)",
"       </td>",
"       <td>",
"        15 versus 7 (p = 0.01)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IB2",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        797",
"       </td>",
"       <td>",
"        17 versus 13 (NSS)",
"       </td>",
"       <td>",
"        37 versus 21 (p&lt;0.01)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AdenoCA: adenocarcinoma; SCC: squamous cell carcinoma; NSS: not statistically significant.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eifel, P. Gynecol Oncol 1995; 59:38.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16651=[""].join("\n");
var outline_f16_16_16651=null;
var title_f16_16_16652="Overview Rx fVIII inhibitor";
var content_f16_16_16652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of bleeding episodes in hemophilic patients with factor VIII inhibitors according to inhibitor titer and responder status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Patients who are known to be high responders to factor VIII concentrates should not receive blood products containing factor VIII for minor bleeding episodes to avoid an anamnestic response. In this setting, the patient can usually be controlled with conservative measures plus prothrombin complex concentrates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with significant bleeding who are low responders and have a low inhibitor titer (&lt;5 Bethesda units) against factor VIII can be treated with high purity factor VIII concentrates at a bolus dose of 50 to 150 units/kg or two to three times the patient's usual dose, followed by a continuous infusion of 10 units/kg per hour. An alternative is porcine factor VIII at a dose of 50 units/kg. The goal of therapy is to raise the factor VIII level to 30 to 50 units/mL, which is in the hemostatic range.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Independent of responder status, patients with low inhibitor titers (&lt;5 Bethesda units) and minor bleeding can be managed with prothrombin complex concentrates at a dose of 50 to 75 units/kg, repeat once or twice at 8- to 12-hour intervals as necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with inhibitor titers between 5 and 10 Bethesda units should receive higher doses of human factor VIII or porcine factor VIII (75 to 100 units/kg).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with inhibitor titers that are above 10 Bethesda units for human factor VIII but below this level for porcine factor VIII can be given a high dose of porcine factor VIII (100 units/kg).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with moderately high inhibitor titers between 10 and 30 Bethesda units for both human and porcine factor VIII can undergo a 1.5 volume plasmapheresis or immunoadsorption to reduce the inhibitor titer by 50 to 66 percent; this can be followed by the administration of human or porcine factor VIII. An alternative in such patients is the administration of prothrombin complex concentrates or, if the porcine factor VIII titer is below 10 Bethesda units, porcine factor VIII concentrates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with very high inhibitor titers above 30 Bethesda units can only be treated with prothrombin complex concentrates, porcine factor VIII concentrates (100 to 150 units/kg), or recombinant human factor VIIa.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Porcine factor VIII products are NOT COMMERCIALLY AVAILABLE at this time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Feinstein DI. Inhibitors in hemophilia: In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al, Churchill Livingstone, New York 2000. p.1504.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16652=[""].join("\n");
var outline_f16_16_16652=null;
var title_f16_16_16653="Timing of nocturnal asthma";
var content_f16_16_16653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Timing of dyspneic episodes in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 218px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of dyspneic episodes in 3129 mainly asthmatic patients. Most of the episodes occurred at night.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Dethlefsen, U, Repgas, R, Clin Med 1985; 80:44.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16653=[""].join("\n");
var outline_f16_16_16653=null;
var title_f16_16_16654="Contents: Other topics in dermatology";
var content_f16_16_16654=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Other topics in dermatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Other topics in dermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Basic dermatologic procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31543\">",
"           Dermatologic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/45/40660\">",
"           Intralesional injection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of eccrine and apocrine glands",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/7/6265\">",
"           Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1257\">",
"           Primary focal hyperhidrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24266\">",
"           Treatment of hidradenitis suppurativa",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of oral mucosa and genitalia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5336\">",
"           Dermatitis of the vulva",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/11/25786\">",
"           Oral lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26361\">",
"           Oral lichen planus: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/11/41144\">",
"           Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6874\">",
"           Vulvar lichen sclerosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drugs used in dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27752\">",
"           General principles of dermatologic therapy and topical corticosteroid use",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1847\">",
"           Keloids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/34/553\">",
"           Overview of benign lesions of the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/61/37846\">",
"           Paronychia and ingrown toenails",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10090\">",
"           Pruritus: Etiology and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/58/6058\">",
"           Pruritus: Overview of management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lichen sclerosus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28952\">",
"           Extragenital lichen sclerosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6874\">",
"           Vulvar lichen sclerosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mastocytosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/1/6170\">",
"           Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18650\">",
"           Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41767\">",
"           Treatment and prognosis of cutaneous mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39817\">",
"           Treatment and prognosis of systemic mastocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/24/22922\">",
"           Granuloma annulare",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31381\">",
"           Grover's disease (transient and persistent acantholytic dermatosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4774\">",
"           Management of intergluteal pilonidal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7285\">",
"           Metabolic and inherited diseases affecting the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/50/37672\">",
"           Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/49/13080\">",
"           Pathologic skin picking",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/23/41334\">",
"           Treatment of erythema multiforme",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin disorders in pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29657\">",
"           Dermatoses of pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-A56D976D5B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_16_16654=[""].join("\n");
var outline_f16_16_16654=null;
var title_f16_16_16655="Dissection of the abdominal aorta on longitudinal ultrasound";
var content_f16_16_16655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the abdominal aorta on longitudinal ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis view shows a dissection of the abdominal aorta (AAo) and the presence of a spiral flap (f).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_16_16655=[""].join("\n");
var outline_f16_16_16655=null;
